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ABSTRACT: The first enantioselective formal [3+2] cycloaddition between α-
isocyanoesters and trifluoromethylketones to give 5-trifluoromethyl-2-oxazolines 
bearing two contiguous stereogenic centers, one of them being a quaternary stereocenter 
substituted with a CF3 group has been developed. The reaction is based upon a 
multicatalytic approach that combines a bifunctional Brønsted base-squaramide 
organocatalyst and Ag+ as Lewis acid. The reaction could be achieved with a range of 
aryl and heteroaryl trifluoromethyl ketones and the resulting oxazolines were obtained 
with good to excellent diastereo- and enantioselectivity. 
INTRODUCTION 
The 2-oxazoline moiety is present in a large number of natural products, drugs and 
bioactive compounds.1 Chiral oxazolines have also found important applications in 
organic synthesis as ligands in asymmetric catalysis,2 as well as synthetic intermediates 
for 1,2-aminoalcohols and other relevant compounds.3 In recent years, the 
enantioselective formal [3+2] cycloaddition of α-isocyanoesters with carbonyl 
compounds has emerged as an elegant and powerful strategy for the construction of 
chiral substituted 2-oxazolines bearing two adjacent stereocenters and considerable 
success on this reaction has been obtained with aldehydes4 and, in less extent, with 
ketones.5 
On the other hand, the introduction of trifluoromethyl substituents6 into organic 
molecules has attracted great attention in the field of medicinal chemistry because of the 
significant impact of the trifluoromethyl group on the metabolic stability and 
bioavailability of drugs.7 For these reasons, different strategies have been devised for 
the synthesis of trifluoromethylated heterocycles, involving either the 
trifluoromethylation of non-fluorinated heterocycles8 or cycloaddition/cyclization 
reactions from trifluoromethylated building blocks.9 In this context, the 5-
trifluoromethyl-2-oxazoline moiety is especially appealing as it is a synthetic precursor 
for fluorinated non-proteinogenic amino acids and trifluoromethyl amino alcohols, 
which have important applications in medicinal chemistry10 and biochemical studies,11 
and as conformational modifiers in physiologically active proteins and enzymes.12 
Herein we report the enantioselective formal [3+2] cycloaddition between α-
isocyanoesters and trifluoromethylketones to give 5-trifluoromethyl-2-oxazolines 
bearing two contiguous stereogenic centers, one of them being a quaternary stereocenter 
substituted with a CF3 group (Scheme 1). Although such reaction has been 
diastereoselectively performed, a catalytic asymmetric version has not been developed 
so far, to the best of our knowledge.13  
Scheme 1. Formal [3+2] cycloaddition between trifluoromethylketones and α-
































RESULTS AND DISCUSSION 
Recently, based on a cooperative strategy previously reported by Escolano et al. for the 
asymmetric cycloaddition of isocyanoacetates with vinyl ketones,14 our group developed 
a highly catalytic enantioselective cycloaddition reaction between ketones and α-
isocyanoesters using a multicatalytic approach that combined a bifunctional Brønsted 
base-squaramide organocatalyst and Ag+ as Lewis acid (Scheme 1).5d  



































































Entry SQ t (h) Yield (%)b trans:cisc eetrans/cis (%)d 
1e I 72 - - - 
2 I 0.5 >95 99:1 77/57 
3 II 0.5 85 99:1 -66/-28f 
4 III 0.5 >95 95:5 83/61 
5 IV 17 >95 95:5 81/56 
6 V 0.5 50 100:-- 67/-- 
7 VI 5 >95 50:50 29/70 
8 VII 0.5 >95 85:15 58/33 
9 VIII 0.5 >95 79:21 78/65 
a 1a (0.25 mmol), 2a (0.33 mmol), SQ (0.026 mmol), Ag2O (0.0125 mmol), MTBE (2 mL), 0 °C. b Yield 
of isolated product. c Determined by 1H NMR. d Determined by HPLC over chiral chromatography 
phases. e Reaction carried out in absence of silver salt. No advance was observed after the indicated time. f 
The opposite enantiomer was obtained. 
Following this approach,14 we tested the reaction of trifluoroacetophenone (1a) and 
methyl isocyanoacetate (2a) in the presence of several bifunctional squaramides (SQ, 10 
mol %) and Ag2O (5 mol %) in methyl tert-butyl ether (MTBE) at 0 °C (Table 1, see 
also Tables S1-S3 in SI). The reaction did not proceed in the absence of Ag2O (Table 1, 
entry 1). On the other hand, all the squaramides tested in combination with silver oxide 
provided oxazoline 3a in good yields and in a short reaction time. The trans 
diastereomer was obtained diastereoselectively in all the cases except with squaramide 
VI (Table 1, entry 7). The best result in terms of enantioselectivity was obtained with 
squaramide III, derived from dihydroquinine and 3,5-bis(trifluoromethyl)aniline, that 
provided oxazoline 3a in almost quantitative yield with 95:5 dr and 83% ee for the 
major diastereomer (Table 1, entry 4). 
A strong concentration effect was also found, the diastereo- and enantioselectivity of the 
reaction increasing with the dilution of the reaction mixture (Table 2, entries 1-3). The 
use of 1:2 squaramide/Ag2O ratio increased the diastereoselectivity but unfortunately 
lowered the enantioselectivity (Table 2, entry 4). Notably, the use of a 1:1 
squaramide/Ag2O mixture provided similar results to the initially tested 2:1 mixture, 
being possible to reduce the catalyst load to 2.5 mol % without noticeable effect on the 
stereoselectivity (Table 2, entries 3 and 5).  
Table 2. Effect of concentration and squaramide/Ag2O ratioa 
Entry [1a]b III:Ag2O t (h) Yield(%)c trans:cisd eetrans(%)e 
1 0.13 2:1 0.5 >95 95:5 83 
2 0.26 2:1 0.5 >95 87:13 75 
3 0.033 2:1 4 >95 96:4 90 
4f 0.033 1:2 3 90 99:1 82 
5g 0.033 1:1 18 >95 94:6 90 
a 1a (0.25 mmol), 2a (0.33 mmol), III (0.026 mmol), Ag2O (0.0125 mmol), MTBE, 0 °C. b Molar 
concentration. c Yield of isolated product. d Determined by 1H NMR. e Determined by HPLC over chiral 
chromatography phases. f III (0.0065 mmol). g III (0.0033 mmol). 
Under the optimized conditions, the scope of the reaction of methyl isocyanoacetate 
(2a) and several substituted trifluoroacetophenones 1 was studied (Table 3).15 In 
general, the presence of substituents at the ortho or para positions of the aromatic ring 
brought about some decrease of enantioselectivity whilst the meta-substituted 
trifluoroacetophenones gave similar or higher enantiomeric excesses than ketone 1a 
(Table 3, entries 5-7). A negative effect of electron-withdrawing groups on the 
diastereoselectivity was also observed (Table 3, entries 4, 9 and 10). The heterocyclic 
trifluoroacetylthiophene (1k) proved to be a suitable substrate that reacted with good 
diastereo- and enantioselectivity (Table 2, entry 11). Alkyl-substituted 
trifluoromethylketones 1l and 1m were also tested, which provided oxazolines 3l and 
3m, respectively, with moderate diastereo- and enantioselectivity (Table 2, entries 12 
and 13). Finally, the reaction was scaled up to 1.25 mmol of compound 1a, obtaining 
oxazoline 3a without any noticeable loss of efficiency, indicating the robustness of the 
method (Table 3, entry 14). 
Table 3. Enantioselective reaction of trifluoromethylketones and methyl 























Entry 1 R t (h) 3 yield (%)b trans:cisc eetrans (%)d 
1 1a Ph 4 3a >95 96:4 90 
2 1b 4-MeC6H4 5 3b >95 94:6 87 
3 1c 4-MeOC6H4 3.5 3c 88 96:4 85 
4 1d 4-ClC6H4 4 3d >95 80:20 84 
5 1e 3-MeC6H4 5 3e >95 94:6 90 
6 1f 3-MeOC6H4 4 3f 94 92:8 88 
7 1g 3-BrC6H4 3.5 3g 95 86:14 92 
8 1h 2-MeOC6H4 16 3h >95 99:1 85 
9 1i 2-BrC6H4 14 3i 93 85:15 70 
10 1j 3,4-Cl2C6H3 16 3j >95 77:23 85 
11 1k 2-thienyl 5.5 3k >95 92:8 90 
12 1l PhCH2CH2 15 3l 66 86:14 81 
13 1m CH3 7 3m 80 92:8 82 
14e 1a Ph 2 3a >95 92:8 90 
a 1a (0.25 mmol), 2a (0.33 mmol), III (0.0063 mmol), Ag2O (0.0063 mmol), MTBE (8 mL), 0 °C. b Yield 
of isolated product. c Determined by 1H NMR. d Determined by HPLC over chiral chromatography 
phases. e Reaction scaled up to 1.25 mmol of 1a. 
The configuration of the stereogenic centers in compound trans-3g was determined as 
(4S,5S) after hydrolysis and X-ray analysis of the resulting amino alcohol 7g (Scheme 
2).16 For the remaining compounds 3, the stereochemistry was assigned under the 
assumption of a uniform mechanistic pathway.17 
Table 4. Enantioselective reaction of trifluoromethylketones and tert-butyl 























Entry 1 R t (d) 4 Yield (%)b trans:cisc eetrans/cis (%)d 
1 1a Ph 1 4a >95 70:30 96/90 
2 1b 4-MeC6H4 7 4b 87 66:34 93/96 
3 1c 4-MeOC6H4 7 4c >95 63:37 84/77 
4 1d 4-ClC6H4 1 4d >95 53:47 96/90 
5 1e 3-MeC6H4 6 4e 94 76:24 97/87 
6 1f 3-MeOC6H4 4 4f 84 72:28 97/85 
7 1g 3-BrC6H4 1 4g >95 64:36 97/90 
8 1h 2-MeOC6H4 12 4h 80 94:6 94/70 
9 1i 2-BrC6H4 3 4ie >95 99:1 91/nd 
10 1j 3,4-Cl2C6H3 1 4j >95 53:47 94/85 
11 1k 2-thienyl 1 4k >95 62:38 97/91 
12 1l CH2CH2Ph 1 4l 83 72:28 84/87 
a 1 (0.25 mmol), 2b (0.33 mmol), VIII (0.0063 mmol), Ag2O (0.0063 mmol), MTBE (8 mL), 0 °C. b 
Yield of isolated product. c Determined by 1H NMR. d Determined by HPLC over chiral chromatography 
phases. e Structure determined by X-ray analysis (see ref. 16). 
Next, we tested the performance of other isocyano esters having different alkoxy groups 
(see Table S4 in SI). tert-Butyl isocyanoacetate seemed to promote the highest 
enantioselectivity using squaramide VIII instead of III. The reaction of 
trifluoromethylketones 1 with tert-butyl isocyanoacetate (2b) showed a similar substrate 
scope as the reaction with the methyl ester. In general the reaction took place with 
moderate to good diastereoselectivity and high to excellent enantioselectivity for the 
major diastereomer (Table 4). X-Ray analysis of compound 4i16 allowed us to assign the 
absolute sterochemistry of compounds 4 as (4S,5S), indicating a similar stereochemical 
pathway as the reaction with methyl isocyanoacetate.17 
Table 5. Enantioselective reaction of trifluoromethylketones and methyl 2-























Entry 1 R t (d) 5 Yield (%)b trans:cisc eecis (%)d 
1 1a Ph 1 5a 89 15:85 90 
2 1c 4-MeOC6H4 3 5c 42 21:79 89 
3 1d 4-ClC6H4 1 5d >95 10:90 89 
4 1n 4-BrC6H5 2 5n 82 13:87 89 
5 1e 3-MeC6H4 1 5e 86 1:99 90 
6 1f 3-MeOC6H4 3 5f 86 15:85 89 
7 1g 3-BrC6H4 7 5g 81 2:98 88 
8 1h 2-MeOC6H4 5 5h -e - - 
a 1 (0.25 mmol), 2c (0.33 mmol), VIII (0.0125 mmol), Ag2O (0.0063 mmol), MTBE (2 mL), –20 °C. b 
Yield of isolated product. c Determined by 1H NMR. d Determined by HPLC over chiral chromatography 
phases. e No advance observed after 5 days. 
Finally, the reaction of several trifluoromethylketones 1 with methyl 2-isocyano-2-
phenylacetate (2c) to give oxazolines 5 bearing two contiguous quaternary stereocenters 
was achieved in the presence of squaramide VIII and Ag2O (Table 5).18 In this case, the 
reaction worked better under higher concentration and with a 2:1 ratio of 
squaramide/Ag2O and yielded the cis diastereomer as the major one.17 Fair to good 
diastereomeric ratios and high enantiomeric excesses were obtained for 
trifluoroacetophenone derivatives having electron-donating or slightly electron-
withdrawing groups. However, the reaction did not proceed with ortho-substituted 
trifluoroacetophenones. 
Tosylmethylisocyanide (TOSMIC) was also tested in the reaction with 
trifluoromethylketone 1a, although, unfortunately, no reaction was observed under any 
of the optimized conditions. 
The prepared oxazolines are synthetic precursors for trifluoromethylated amino 
alcohols. Thus, treatment of oxazolines 3a or 3g with aqueous HCl in THF gave almost 
quantitative yields of hydroxyformamides 6a or 6g, respectively, with a minor decrease 
of ee. On the other hand, treatment of 3a or 3g with aqueous hydrochloric acid in 
MeOH yielded amino alcohols 7a and 7g in high yields, without erosion of 
enantiomeric excesses (Scheme 2).  
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 a Structure determined by X-ray analysis (see ref. 16) 
Furthermore, oxazoline 3m, prepared in 82% ee from methyl isocyanoacetate and 1,1,1-
trifluoroacetone (Table 1, entry13), upon treatment with aqueous HCl in methanol for 
72 hours, could be transformed into amino alcohol 7m (82% ee), a known intermediate 
in the synthesis of LPC-083, which is an inhibitor of LpxC, an essential enzyme of the 
lipid A biosynthetic pathway in Gram-negative bacteria and a validated antibiotic target 
(Scheme 3).19   
Scheme 3. Formal enantioselective synthesis of LPC-083 
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In summary, we have developed the first catalytic enantioselective formal [3+2] 
cycloaddition of trifluoromethylketones and isocyanoacetates. Using a multicatalytic 
approach that combines a bifunctional Brønsted base-squaramide organocatalyst and 
Ag+ as Lewis acid we were able to obtain chiral oxazolines bearing a quaternary 
stereocenter substituted with a trifluoromethyl group and a contiguous tertiary or 
quaternary stereocenter. The reaction was broad in scope and provided a straightforward 
access to chiral trifluoromethylated hydroxy amino esters. 
EXPERIMENTAL SECTION 
General Experimental Methods. Formal [3+2] cycloaddition reactions were carried 
out in round bottom flasks closed with a stopper. Starting materials, including 
trifluoromethylketones, methyl and t-butyl isocyanoacetate were obtained from 
commercial sources. Methyl tert-butyl ether (MTBE) was stored over 4 Å MS until it 
was used. Reactions were monitored by TLC analysis using Merck Silica Gel 60 F-254 
thin layer plates. Flash column chromatography was performed on Merck silica gel 60, 
0.040-0.063 mm. Melting points were determined in capillary tubes. Unless otherwise 
stated, NMR spectra were run at 300 MHz for 1H and at 75 MHz for 13C NMR using 
residual nondeuterated solvent (CHCl3) as internal standard (δ 7.26 and 77.0 ppm, 
respectively), and at 282 MHz for 19F NMR using CFCl3 as internal standard. Chemical 
shifts are given in ppm. The carbon type was determined by DEPT experiments. High 
resolution mass spectra (ESI) were recorded on a Q-TOF spectrometer equipped with an 
electrospray source with a capillary voltage of 3.3 kV (ESI). Specific optical rotations 
were measured using sodium light (D line 589 nm). Chiral HPLC analyses were 
performed in a chromatograph equipped with a UV diode-array detector using chiral 
stationary phase columns from Daicel or Phenomenex. Chiral GLC analyses were 
carried out in a chromatograph equipped with a flame ionization detector using nitrogen 
(1 mL/min) as carrier gas, Tinjector = 220 ◦C, Tdetector = 220 ◦C. 
General procedure for the enantioselective formal [3+2] cycloaddition reaction 
with methyl isocyanoacetate. 
Squaramide III (3.9 mg, 0.0063 mmol) and silver oxide (1.5 mg, 0.0063 mmol) were 
introduced in a 25 mL round bottom flask followed by MTBE (8 mL) and 
trifluoroacetophenone 1 (0.25 mmol). The flask was closed with a stopper and 
introduced in an ice bath. After 5 min, methyl isocyanoacetate (2a, 30 µL, 0.33 mmol) 
was added and the mixture was stirred at 0 °C until consumption of the 
trifluoroacetophenone 1 (TLC). After this time, the reaction mixture was filtered 
through a short pad of silica gel and concentrated under reduced pressure. A small 
aliquot was analyzed by 1H NMR to determine the diastereomer ratio and by HPLC to 
determine the enantiomeric excess of products 3. The remaining crude was 
chromatographed on silica gel eluting with hexane:EtOAc mixtures (9:1 to 8:2) to 
obtain the oxazolines 3.20 
The racemic products were obtained by a similar procedure using N-[3,5-
bis(trifluoromethyl)phenyl]-N’-(3-dimethylaminopropyl)squaramide as a substitutive 
for squaramide III. 
Methyl 5-phenyl-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (3a). Colorless 
oil (83.4 mg, >95% from 55.0 mg of 1a). HPLC (Chiracel IC, hexane:iPrOH 95:5, 0.7 
mL/min): trans-(4S,5S)-3a (major diastereomer, 90% ee): major enantiomer, tr = 12.4 
min, minor enantiomer 18.3 min; cis-3a (minor diastereomer): major enantiomer, tr = 
22.6 min, minor enantiomer tr = 28.6 min; dr trans:cis = 96:4. trans-(4S,5S)-3a (major 
diastereomer): [α]D25 +143.0 (c 0.30, CHCl3, for the diastereomer mixture); 1H NMR 
(300 MHz, CDCl3), δ 7.44-7.43 (2H, m, Ar), 7.39-7.37 (3H, m, Ar), 7.24 (1H, d, J = 1.8 
Hz, N=CHO), 5.24 (1H, d, J = 1.8 Hz, CH), 3.27 (3H, s, CH3); 13C{1H} NMR (75 
MHz, CDCl3) δ 167.1 (C), 155.7 (CH), 130.7 (C), 129.6 (CH), 128.4 (CH), 125.9 (CH, 
q, JC-F = 1.6 Hz), 123.8 (C, q, JC-F = 283 Hz), 87.6 (C, q, JC-F = 30 Hz), 74.2 (CH), 52.2 
(CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –80.1 (s, CF3); HRMS (ESI) m/z: [M+H]+ 
calcd for C12H11F3NO3+: 274.0686, found: 274.0689. cis-3a (minor diastereomer): 
representative signals taken from the NMR spectra of the diastereomer mixture, 1H 
NMR (300 MHz, CDCl3) δ 7.70-7.35 (5H, Ar), 7.16 (1H, d, J = 2.4 Hz, N=CHO), 5.14 
(1H, dd, J = 2.1, 0.6 Hz, CH), 3.91 (3H, s, CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –
76.0 (s, CF3). 
Methyl 5-(p-tolyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (3b). Colorless 
oil (68.9 mg, >95% from 47.0 mg of 1b). HPLC (Chiralpak AS-H, hexane:iPrOH 95:5, 
1 mL/min): trans-(4S,5S)-3b (major diastereomer, 87% ee): major enantiomer, tr = 6.0 
min, minor enantiomer, tr = 8.6 min; cis-3b (minor diastereomer): major enantiomer, tr = 
15.7 min, minor enantiomer, tr = 17.0 min; dr trans:cis = 94:6. trans-(4S,5S)-3b (major 
diastereomer): [α]D25 +127.8 (c 0.58, CHCl3, for the diastereomer mixture); 1H NMR 
(300 MHz, CDCl3) δ 7.32 (2H, d, J = 8.1 Hz, Ar), 7.23 (1H, d, J = 1.8 Hz, N=CHO), 
7.17 (2H, d, J = 8.1 Hz, Ar), 5.22 (1H, d, J = 2.1 Hz, CH), 3.30 (3H, s, CH3), 2.34 (3H, 
s, CH3); 13C{1H} NMR (75 MHz, CDCl3) δ 167.1 (C), 155.7 (CH), 139.6 (C), 129.0 
(CH), 127.6 (C), 125.7 (CH, q, JC-F = 1.6 Hz), 123.8 (C, q, JC-F = 283 Hz), 87.5 (C, q, JC-
F = 30 Hz), 74.0 (CH), 52.1 (CH3), 21.0 (CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –
80.2 (s, CF3); HRMS (ESI) m/z: [M+H]+ calcd for C13H12F3NO3+: 288.0842, found: 
288.0849. cis-3b (minor diastereomer): representative signals taken from the NMR 
spectra of the diastereomer mixture, 1H NMR (300 MHz, CDCl3) δ 5.12 (1H, dd, J = 
2.1, 0.6 Hz, CH), 3.83 (3H, s, CH3), 2.38 (3H, s, CH3); 19F{1H} NMR (282 MHz, 
CDCl3) δ –76.1 (s, CF3). 
Methyl 5-(4-methoxyphenyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (3c). 
Colorless oil (65.9 mg, 88% from 51.0 mg of 1c). HPLC (Chiralpak IC, hexane:iPrOH 
95:5, 1 mL/min): trans-(4S,5S)-3c (major diastereomer, 85% ee): major enantiomer, tr = 
13.2 min, minor enantiomer, tr = 29.0 min; cis-3c (minor diastereomer): major 
enantiomer, tr = 27.9 min, minor enantiomer, tr = 34.7 min; dr trans:cis = 96:4.  trans-
(4S,5S)-3c (major diastereomer): [α]D25 +122.5 (c 0.25, CHCl3, for the diastereomer 
mixture); 1H NMR (300 MHz, CDCl3) δ 7.35 (2H, d, J = 8.6 Hz, Ar), 7.23 (1H, dd, J = 
2.1, 0.6 Hz, N=CHO), 6.88 (2H, d, J = 9.0 Hz, Ar), 5.20 (1H, d, J = 2.1 Hz, CH), 3.80 
(s, CH3), 3.33 (s, CH3); 13C{1H} NMR (75 MHz, CDCl3) δ 167.2 (C), 160.3 (C), 155.7 
(CH), 127.3 (CH, q, JC-F = 1.9 Hz), 123.8 (C, q, JC-F = 283 Hz), 122.4 (C), 113.8 (CH), 
87.5 (C, q, JC-F = 30 Hz), 74.0 (CH), 55.2 (CH3), 52.3 (CH3); 19F{1H} NMR (282 MHz, 
CDCl3) δ –80.4 (s, CF3); HRMS (ESI) m/z: [M+H]+ calcd for C13H13F3NO4+ : 304.0791, 
found: 304.0795. cis-3c (minor diastereomer): representative signals taken from the 
NMR spectra of the diastereomer mixture, 1H NMR (300 MHz, CDCl3) δ 7.13 (1H, d, J 
= 2.4 Hz, CH), 5.11 (1H, dd, J = 2.1, 0.6 Hz, CH), 3.89 (3H, s, CH3), 3.82 (3H, s, CH3); 
19F{1H} NMR (282 MHz, CDCl3) δ –76.7 (s, CF3). 
Methyl 5-(4-chlorophenyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (3d). 
Colorless oil (75.7 mg, >95% from 54.1 mg of 1d). HPLC (Chiralpak IC, hexane:iPrOH 
90:10, 1 mL/min): trans-(4S,5S)-3d (major diastereomer, 84% ee): major enantiomer, tr 
= 5.9 min, minor enantiomer, tr = 8.1 min; cis-3d (minor diastereomer, 64% ee): major 
enantiomer, tr = 12.7 min, minor enantiomer, tr = 13.1 min; dr trans:cis = 80:20. trans-
(4S,5S)-3d (major diastereomer): [α]D25 +120.8 (c 0.20, CHCl3, 84% ee); 1H NMR (300 
MHz, CDCl3), δ 7.37-7.35 (4H, m, Ar), 7.23 (1H, d, J = 2.1 Hz, N=CHO), 5.23 (1H, d, 
J = 2.1 Hz, CH), 3.33 (3H, s, CH3); 13C{1H} NMR (75 MHz, CDCl3) δ 166.9 (C), 155.6 
(CH), 135.9 (C), 129.3 (C), 128.7 (CH), 127.4 (CH, q, JC-F = 1.6 Hz), 123.6 (C, q, JC-F = 
283 Hz), 87.2 (C, q, JC-F = 30.8 Hz), 74.0 (CH), 52.4 (CH3); 19F{1H} NMR (282 MHz, 
CDCl3) δ –80.2 (s, CF3); HRMS (ESI) m/z: [M+H]+ calcd for C12H10ClF3NO3+: 
308.0296, found: 308.0299. cis-3d (minor diastereomer): [α]D25 +63.5 (c 0.14, CHCl3, 
64% ee);   1H NMR (300 MHz, CDCl3) δ 7.66 (2H, d, J = 8.5 Hz, Ar), 7.45 (2H, d, J = 
8.5 Hz, Ar), 7.16 (1H, d, J = 2.1 Hz, CH), 5.08 (1H, dd, J = 2.1, 0.6 Hz, CH), 3.92 (3H, 
s, CH3); 13C{1H} NMR (75 MHz, CDCl3) δ 167.3 (C), 154.5 (CH), 136.2 (C), 133.5 
(C), 129.2 (CH), 127.9 (CH), 122.6 (C, q, JC-F = 283 Hz), 87.7 (C, q, JC-F = 31 Hz), 76.5 
(CH), 53.3 (CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –76.0 (s, CF3); HRMS (ESI) m/z: 
[M+H]+ calcd for C12H10ClF3NO3+ : 308.0296, found: 308.0299.  
Methyl 5-(m-tolyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (3e): Colorless 
oil (68.8 mg, >95% from 47.0 mg of 1e). HPLC (Chiralpak IC, hexane:iPrOH 95:5, 1 
mL/min): trans-(4S,5S)-3e (major diastereomer, 90% ee): major enantiomer, tr = 8.3 
min, minor enantiomer, tr = 12.0 min; cis-3e (minor diastereomer): major enantiomer, tr 
= 13.8 min, minor enantiomer, tr = 18.2 min; dr trans:cis = 94:6. trans-(4S,5S)-3e 
(major diastereomer): [α]D25 +132.4 (c 0.50, CHCl3, for the diastereomer mixture); 1H 
NMR (300 MHz, CDCl3) δ 7.24-7.15 (5H, m, Ar, N=CHO), 5.22 (1H, d, J = 1.8 Hz, 
CH), 3.30 (3H, s, CH3), 2.36 (3H, d, J = 0.6 Hz, CH3); 13C{1H} NMR (75 MHz, CDCl3) 
δ 167.1 (C), 155.7 (CH), 138.2 (C), 130.6 (C), 130.3 (CH), 128.3 (CH), 126.4 (CH, q, 
JC-F = 1.8 Hz), 123.8 (C, q, JC-F = 283 Hz), 122.9 (CH, q, JC-F = 1.9 Hz), 87.6 (C, q, JC-F 
= 30 Hz), 74.1 (CH), 52.2 (CH3), 21.4 (CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –80.1 
(s, CF3); HRMS (ESI) m/z: [M+H]+ calcd for C13H13F3NO3+: 288.0842, found: 
288.0845. cis-3e (minor diastereomer): representative signals taken from the NMR 
spectra of the diastereomer mixture, 1H NMR (300 MHz, CDCl3) δ 5.13 (1H, dd, J = 
2.1, 0.6 Hz, CH), 3.83 (3H, s, CH3), 2.41 (3H, s, CH3); 19F{1H} NMR (282 MHz, 
CDCl3) δ –75.8 (s, CF3).  
Methyl 5-(3-methoxyphenyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (3f): 
Colorless oil (71.3 mg, 94% from 51.0 mg of 1f). HPLC (Chiralpak AS-H, 
hexane:iPrOH 95:5, 1 mL/min): trans-(4S,5S)-3f (major diastereomer, 88% ee): major 
enantiomer, tr = 7.3 min, minor enantiomer, tr = 10.0 min; cis-3f (minor diastereomer): 
major enantiomer, tr = 21.8 min, minor enantiomer, tr = 19.9 min; dr trans:cis = 92:8. 
trans-(4S,5S)-3f (major diastereomer): [α]D25 −26.7 (c 0.56, CHCl3, for the 
diastereomer mixture); 1H NMR (300 MHz, CDCl3) δ 7.29 (1H, t, J = 8.4 Hz, Ar), 7.22 
(1H, d, J = 2.1 Hz, N=CHO), 7.01-6.98 (2H, m, Ar), 6.92-6.90 (1H, m, Ar), 5.22 (1H, d, 
J = 1.8 Hz, CH), 3.80 (3H, s, CH3), 3.33 (3H, s, CH3); 13C{1H} NMR (75 MHz, CDCl3) 
δ 167.1 (C), 159.5 (C), 155.7 (CH), 132.1 (C), 129.5 (CH), 123.7 (C, q, JC-F = 283 Hz), 
118.1 (CH, q, JC-F = 2.2 Hz), 114.9 (CH), 111.9 (CH, q, JC-F = 1.7 Hz), 87.5 (C, q, JC-F = 
30 Hz), 74.1 (CH), 55.3 (CH3), 52.3 (CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –80.2 
(s, CF3); HRMS (ESI) m/z: [M+H]+ calcd for C13H13F3NO4+:  304.0791, found: 
304.0794. cis-3f (minor diastereomer): representative signals taken from the NMR 
spectra of the diastereomer mixture, 1H NMR (300 MHz, CDCl3) δ 7.14 (1H, d, J = 2.1 
Hz, N=CHO), 5.13 (1H, dd, J = 2.1, 0.6 Hz, CH), 3.91 (3H, s, CH3), 3.84 (3H, s, CH3); 
19F{1H} NMR (282 MHz, CDCl3) δ –75.9 (s, CF3). 
Methyl 5-(3-bromophenyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (3g): 
Colorless oil (83.0 mg, 95% from 63.3 mg of 1g). HPLC (Chiralpak IC, hexane:iPrOH 
95:5, 1 mL/min): trans-(4S,5S)-3g (major diastereomer, 92% ee): major enantiomer, tr 
= 7.3 min, minor enantiomer, tr = 9.8 min; cis-3g (minor diastereomer): major 
enantiomer, tr = 14.5 min, minor enantiomer, tr = 18.3 min; dr trans:cis = 86:14. trans-
(4S,5S)-3g (major diastereomer): [α]D25 +107.7 (c 0.66, CHCl3, for the diastereomer 
mixture); 1H NMR (300 MHz, CDCl3) δ 7.62 (1H, s, Ar), 7.53 (1H, ddd, J = 8.0, 1.9, 
1.1 Hz, Ar), 7.38 (1H, brd, J = 8.0 Hz, Ar), 7.25 (1H, t, J = 8.0 Hz, Ar), 7.23 (1H, d, J = 
1.8 Hz, N=CHO), 5.23 (1H, d, J = 2.1 Hz, CH), 3.36 (3H, s, CH3); 13C{1H} NMR (75 
MHz, CDCl3) δ 166.8 (C), 155.5 (CH), 132.9 (C), 132.8 (CH), 129.9 (CH), 129.1 (CH, 
q, JC-F = 1.7 Hz), 125.4 (C, q, JC-F = 283 Hz), 124.6 (CH, q, JC-F = 1.7 Hz), 122.6 (C), 
86.9 (C, q, JC-F = 30 Hz), 74.1 (CH), 52.4 (CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –
80.1 (s, CF3); HRMS (ESI) m/z: [M+H]+ calcd for C12H10BrF3NO3+: 351.9791, found: 
351.9791. cis-3g (minor diastereomer): representative signals taken from the NMR 
spectra of the diastereomer mixture, 1H NMR (300 MHz, CDCl3) δ 7.15 (1H, d, J = 2.1 
Hz, N=CHO), 5.08 (1H, dd, J = 2.1, 0.6 Hz, CH), 3.90 (3H, s, CH3); 19F{1H} NMR 
(282 MHz, CDCl3) δ –75.8 (s, CF3).  
Methyl 5-(2-methoxyphenyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate 
(3h): White solid (86.3 mg, >95% from 58.1 mg of 1h). HPLC (Chiralpak IC, 
hexane:iPrOH 95:5, 1 mL/min): trans-(4S,5S)-3h (major diastereomer, 85% ee): major 
enantiomer, tr = 11.6 min, minor enantiomer, tr = 15.9 min; cis-3h (minor diastereomer): 
major enantiomer, tr = 17.2 min, minor enantiomer, tr = 26.9 min; dr trans:cis = 99:1. 
trans-(4S,5S)-3h (major diastereomer): mp 129-130 °C; [α]D25 +228.1 (c 0.41, CHCl3, 
for the diastereomer mixture, dr = 98:2); 1H NMR (300 MHz, CDCl3) δ 7.61 (1H, dd, J 
= 7.8, 1.8 Hz, Ar), 7.38 (1H, td, J = 7.5, 1.8 Hz, Ar), 7.13 (1H, d, J = 2.1 Hz, N=CHO), 
7.05 (1H, td, J = 7.8, 1.2 Hz, Ar), 6.86 (1H, dd, J = 8.1, 0.9 Hz, Ar), 5.28 (1H, d, J = 2.1 
Hz, CH), 3.75 (3H, s, CH3), 3.54 (3H, s, CH3); 13C{1H} NMR (75 MHz, CDCl3) δ 167.7 
(C), 155.3 (C), 155.2 (CH), 130.9 (CH), 128.8 (CH), 123.8 (C, q, JC-F = 283 Hz), 120.9 
(CH), 119.8 (C), 110.3 (CH), 86.9 (C, q, JC-F = 30.8 Hz), 72.8 (CH), 54.7 (CH3), 52.1 
(CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –81.9 (s, CF3); HRMS (ESI) m/z: [M+H]+ 
calcd for C13H13F3NO4+: 304.0791, found: 304.0791. 
Methyl 5-(2-bromophenyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (3i): 
Colorless oil (81.7 mg, 93% from 63.3 mg of 1i). HPLC (Chiralpak IC, hexane:iPrOH 
95:5, 1 mL/min): trans-(4S,5S)-3i (major diastereomer, 70% ee): major enantiomer, tr = 
8.9 min, minor enantiomer, tr = 12.6 min; cis-3i (minor diastereomer): major 
enantiomer, tr = 17.8 min, minor enantiomer, tr = 24.3 min; dr trans:cis = 85:15; major 
isomer:, minor isomer: 54% ee. trans-(4S,5S)-3i (major diastereomer): [α]D25 +150.9 (c 
0.43, CHCl3, for the diastereomer mixture, dr = 85:15); 1H NMR (500 MHz, CDCl3, 50 
ºC) δ 7.90 (1H, unresolved d, Ar), 7.73 (1H, dd, J = 8.0, 1.3 Hz, Ar), 7.52 (1H, td, J = 
8.0, 1.0 Hz, Ar), 7.37 (1H, td, J = 8.0, 1.5 Hz, Ar), 7.27 (1H, d, J = 2.0 Hz, N=CHO), 
5.62 (1H, s, CH), 3.72 (3H, s, CH3); 13C{1H} NMR (125 MHz, CDCl3, 50 ºC) δ 167.4 
(C), 155.0 (CH), 136.3 (C), 134.6 (br CH), 130.8 (CH), 130.4 (CH), 127.6 (CH), 123.7 
(C, q, JC-F = 283 Hz), 120.8 (C), 88.8 (C, q, JC-F = 29 Hz), 72.9 (CH), 52.6 (CH3); 
19F{1H} NMR (282 MHz, CDCl3) δ –79.4 (s, CF3); HRMS (ESI) m/z: [M+H]+ calcd for 
C12H10BrF3NO3+ :351.9791, found: 351.9798. cis-3i (minor diastereomer): 
representative signals taken from the NMR spectra of the diastereomer mixture, 1H 
NMR (300 MHz, CDCl3) δ 7.93 (br d, J = 8.1 Hz, Ar), 7.83 (1H, dd, J = 8.1, 1.3 Hz, 
Ar),  7.52 (1H, td, J = 8.0, 1.0 Hz, Ar), 7.39 (1H, td, J = 8.0, 1.5 Hz, Ar), 7.26 (1H, d, J 
= 2.0 Hz, N=CHO), 5.62 (1H, s, CH), 3.98 (3H, s, CH3); 19F{1H} NMR (282 MHz, 
CDCl3) δ –72.2 (s, CF3). 
Methyl 5-(3,4-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate 
(3j): Yellow oil (90.1 mg, >95% from 64.1 mg of 1j). HPLC (Chiralpak IC, 
hexane:iPrOH 95:5, 1 mL/min): trans-(4S,5S)-3j (major diastereomer, 85% ee): major 
enantiomer, tr = 6.4 min, minor enantiomer, tr = 8.7 min; cis-3j (minor diastereomer): 
major enantiomer, tr = 16.4 min, minor enantiomer, tr = 19.6 min; dr trans:cis = 77:23. 
trans-(4S,5S)-3j (major diastereomer): [α]D25 +105.0 (c 0.92, CHCl3, for the 
diastereomer mixture); 1H NMR (300 MHz, CDCl3) δ 7.56 (1H, d, J = 2.3 Hz, Ar), 7.46 
(1H, d, J = 8.7 Hz, Ar), 7.27 (1H, ddd, J = 8.4, 2.1, 0.9 Hz, Ar), 7.22 (1H, d, J = 1.8 Hz, 
N=CHO), 5.22 (1H, d, J = 1.8 Hz, CH), 3.40 (3H, s, CH3); 13C{1H} NMR (75 MHz) δ 
166.7 (C), 155.4 (CH), 134.3 (C), 133.1 (C), 131.0 (C), 130.5 (CH), 128.2 (CH, q, JC-F 
= 1.8 Hz), 125.4 (CH, q, JC-F = 1.7 Hz), 125.2 (C, q, JC-F = 283 Hz), 86.6 (C, q, JC-F = 29 
Hz), 74.0 (CH), 52.5 (CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –80.2 (s, CF3); HRMS 
(ESI) m/z: [M+H]+ calcd for C12H9Cl2F3NO3+: 341.9906, found: 341.9909. cis-3j (minor 
diastereomer): representative signals taken from the NMR spectra of the diastereomer 
mixture, 1H NMR (300 MHz, CDCl3) δ 7.14 (1H, d, J = 2.1 Hz, N=CHO), 5.05 (1H, dd, 
J = 2.1, 0.9 Hz, CH), 3.91 (3H, s, CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –76.0 (s, 
CF3). 
Methyl 5-(thiophen-2-yl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (3k): 
Yellow oil (80.1 mg, >95% from 52.3 mg of 3k). HPLC (Chiralpak IC, hexane:iPrOH 
95:5, 1 mL/min): trans-(4S,5S)-3k (major diastereomer, 90% ee): major enantiomer, tr 
= 10.0 min, minor enantiomer, tr = 13.8; cis-3k (minor diastereomer): major enantiomer, 
tr = 17.6 min, minor enantiomer, tr = 22.1 min; dr trans:cis = 92:8. trans-(4S,5S)-3k 
(major diastereomer): [α]D25 +48.0 (c 0.79, CHCl3, for the diastereomer mixture); 1H 
NMR (300 MHz, CDCl3) δ 7.36 (1H, dd, J = 5.1, 1.5 Hz, Ar), 7.19 (1H, dd, J = 2.1, 0.6 
Hz, N=CHO), 7.10-7.08 (1H, m, Ar), 7.03 (1H, dd, J = 5.1, 3.9 Hz, Ar), 5.22 (1H, d, J = 
2.1 Hz, CH), 3.41 (3H, s, CH3); 13C{1H} NMR (75 MHz, CDCl3) δ 166.7 (C), 155.1 
(CH), 132.7 (C), 127.5 (CH), 126.9 (CH), 126.8 (CH, q, JC-F = 2.1 Hz), 123.2 (C, q, JC-F 
= 283 Hz), 86.3 (C, q, JC-F = 32 Hz), 74.6 (CH), 52.4 (CH3); 19F{1H} NMR (282 MHz, 
CDCl3) δ –81.5 (s, CF3); HRMS (ESI) m/z: [M+H]+ calcd for C10H9F3NO3S+: 280.0250, 
found: 280.0253. cis-3k (minor diastereomer): representative signals taken from the 
NMR spectra of the diastereomer mixture, 1H NMR (300 MHz, CDCl3) δ 7.12 (1H, d, J 
= 2.1 Hz, N=CHO), 5.19 (1H, dd, J = 2.1, 0.6 Hz, CH), 3.89 (3H, s, CH3); 19F{1H} 
NMR (282 MHz, CDCl3) δ –76.4 (s, CF3). 
Methyl 5-phenethyl-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (3l): Yellow 
oil (50.1 mg, 66% from 51.0 mg of 1l). HPLC (Chiralpak IC, hexane:iPrOH 95:5, 1 
mL/min): trans-(4S,5S)-3l (major diastereomer, 81% ee): major enantiomer, tr = 7.9 
min, minor enantiomer, tr = 19.6 min; cis-3l (minor diastereomer): major enantiomer, tr 
= 39.5 min, minor enantiomer, tr = 28.4 min; dr trans:cis = 86:14. trans-(4S,5S)-3l 
(major diastereomer): [α]D25 +17.5 (c 0.81, CHCl3, for the diastereomer mixture); 1H 
NMR (300 MHz, CDCl3) δ 7.30-7.26 (4H, m, Ar), 7.13-7.10 (1H, m, Ar), 7.03 (1H, d, J 
= 2.4 Hz, N=CHO), 4.98 (1H, d, J = 2.4 Hz, CH), 3.81 (3H, s, CH3), 2.78-2.55 (2H, m, 
CH2), 2.33-2.06 (2H, m, CH2); 13C{1H} NMR (75 MHz, CDCl3) δ 168.1 (C), 155.2 
(CH), 139.9 (C), 128.6 (CH), 128.1 (CH), 126.4 (CH), 124.2 (C, q, JC-F = 283 Hz), 85.7 
(C, q, JC-F = 30.1 Hz), 71.3 (CH), 52.8 (CH3), 31.4 (CH2), 28.6 (CH2); 19F{1H} NMR 
(282 MHz, CDCl3) δ –80.7 (s, CF3); HRMS (ESI) m/z: [M+H]+ calcd for C14H15F3NO3+ 
: 302.0999, found: 302.1004. cis-3l (minor diastereomer): representative signals taken 
from the NMR spectra of the diastereomer mixture, 1H NMR (300 MHz, CDCl3) δ 4.82 
(1H, d, J = 2.1 Hz, CH), 3.81 (3H, s, CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –76.3 
(s, CF3). 
Methyl 5-methyl-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (3m): Volatile 
colorless oil (42.2 mg, 80% from 28.1 mg of 1m). HPLC (Chiralpak IC, hexane:iPrOH 
90:10, 1 mL/min): trans-(4S,5S)-3m (major diastereomer 82%): major enantiomer, tr = 
6.9 min, minor enantiomer, tr = 8.5 min; cis-3m (minor diastereomer): major 
enantiomer, tr = 12.7 min, minor enantiomer, tr = 14.0 min; dr trans:cis = 92:8. trans-
(4S,5S)-3m (major diastereomer): [α]D25 +75.3 (c 0.33, CHCl3, for the diastereomer 
mixture); 1H NMR (300 MHz, CDCl3) δ 6.97 (1H, d, J = 1.5 Hz, N=CHO), 4.88 (1H, d, 
J = 2.5 Hz, CH), 3.79 (3H, s, CH3), 1.49 (3H, m, CH3); 13C{1H} NMR (75 MHz, 
CDCl3) δ 168.0 (C), 155.5 (CH), 124.0 (C, q, JC-F = 283 Hz), 83.9 (C, q, JC-F = 32 Hz), 
71.3 (CH), 52.7 (CH3), 15.3 (CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –83.3 (s, CF3); 
HRMS (ESI) m/z: [M+H]+ calcd for C7H9F3NO3+: 212.0529, found: 212.0536. cis-3m 
(minor diastereomer): representative signals taken from the NMR spectra of the 
diastereomer mixture, 1H NMR (300 MHz, CDCl3) δ 4.62 (1H, dd, J = 2.2, 0.6 Hz, CH), 
3.79 (3H, s, CH3), 1.74 (3H, s, CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –77.7 (s, 
CF3).   
General procedure for the enantioselective formal [3+2] cycloaddition reaction 
with tert-butyl isocyanoacetate. 
Squaramide VIII (6.8 mg, 0.0125 mmol) and silver oxide (1.5 mg, 0.0063 mmol) were 
introduced in a round bottom flask followed by MTBE (8 mL) and 
trifluoroacetophenone 1 (0.25 mmol). The flask was closed with a stopper and 
introduced in an ice bath. After 5 min, tert-butyl isocyanoacetate (2b, 48 µL, 0.33 
mmol) was added and the mixture was stirred at 0 ºC until consumption of the 
trifluoroacetophenone 1 (TLC). After this time, the reaction mixture was filtered 
through a short pad of silica gel and concentred under reduced pressure. A small aliquot 
was analyzed by 1H NMR to determine the diastereomer ratio and by HPLC to 
determine the enantiomeric excess of products 4. The remaining crude was 
chromatographed on silica gel eluting with hexane:EtOAc mixtures (9:1 to 8:2) to 
obtain compounds 4.20 
The racemic product was obtained using a similar procedure using the catalyst 3-((3,5-
bis(trifluoromethyl)phenyl)amino)-4-((3-(dimethylamino)propyl)amino)cyclobut-3-ene-
1,2-dione and silver oxide. 
tert-Butyl 5-phenyl-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (4a): 
Colorless oil (102.2 mg, >95% from 57.3 mg of 1a). HPLC (Chiralpak IC, 
hexane:iPrOH 90:10, 0.7 mL/min): trans-(4S,5S)-4a (major diastereomer, 96% ee): 
major enantiomer, tr = 7.2 min, minor enantiomer, tr = 8.5 min; cis-4a (minor 
diastereomer, 90% ee): major enantiomer, tr = 11.1 min, minor enantiomer, tr = 15.2 
min; dr trans:cis = 70:30. trans-(4S,5S)-4a (major diastereomer): [α]D25 +178.1 (c 1.15, 
CHCl3, 96% ee); 1H NMR (CDCl3, 300 MHz) δ 7.50-7.46 (2H, m, Ar), 7.39-7.37 (3H, 
m, Ar), 7.20 (1H, d, J = 1.8 Hz, N=CHO), 5.08 (1H, d, J = 1.8 Hz, CH), 1.03 (9H, s, 
CH3); 13C{1H} NMR (CDCl3, 75 MHz) δ 165.3 (C), 155.3 (CH), 131.0 (C), 129.4 (CH), 
128.4 (CH), 126.4 (CH, q, JC-F = 2.0 Hz), 123.9 (C, q, JC-F = 284 Hz), 87.6 (C, q, JC-F = 
30 Hz), 82.7 (C), 74.6 (CH), 27.1 (CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –80.3 (s, 
CF3); HRMS (ESI) m/z: [M+H]+ calcd for C15H17F3NO3+: 316.1155, found: 316.1154. 
cis-4a (minor diastereomer): [α]D25 +77.2 (c 0.23, CHCl3, 90% ee); 1H NMR (300 
MHz, CDCl3) δ 7.72-7.69 (2H, m, Ar), 7.46-7.44 (3H, m, Ar), 7.12 (1H, d, J = 2.4 Hz, 
N=CHO), 5.02 (1H, dd, J = 2.1, 0.6 Hz, CH), 1.58 (9H, s, CH3); 13C{1H} NMR (75 
MHz, CDCl3) δ 165.7 (C), 154.0 (CH), 135.6 (C), 129.7 (CH), 128.7 (CH), 128.6 (C, q, 
JC-F = 283 Hz), 126.4 (CH), 123.0 (C, q, JC-F = 283 Hz), 87.9 (C, q, JC-F = 30.7 Hz), 
83.6 (C), 77.4 (CH), 27.7 (CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –75.0 (s, CF3); 
HRMS (ESI) m/z: [M+H]+ calcd for C15H17F3NO3+ : 316.1155, found: 316.1154.  
tert-Butyl 5-(p-tolyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (4b): White 
solid (71.7 mg, 87% from 47.0 mg of 1b). HPLC (Chiralpak IC, hexane:iPrOH 95:5, 1 
mL/min): trans-(4S,5S)-4b (major diastereomer, 93% ee): major enantiomer, tr = 6.9 
min, minor enantiomer, tr = 9.4 min; cis-4b (minor diastereomer, 96% ee): major 
enantiomer, tr = 12.2 min, minor enantiomer, tr = 18.3 min; dr trans:cis = 66:34. trans-
(4S,5S)-4b (major diastereomer): mp: 63-65 ºC; [α]D25 +153.3 (c 0.96, CHCl3, 93% ee); 
1H NMR (300 MHz, CDCl3) δ 7.35 (2H, d, J = 8.1, Ar), 7.19 (1H, d, J = 2.1 Hz, 
N=CHO), 7.18 (2H, d, J = 8.1 Hz, Ar), 5.05 (1H, d, J = 2.1 Hz, CH), 2.33 (3H, d, J = 
0.9 Hz, CH3), 1.05 (9H, s, CH3); 13C{1H} NMR (75 MHz, CDCl3) δ 165.4 (C), 155.3 
(CH), 139.4 (C), 129.0 (CH), 128.0 (C), 126.3 (CH, q, JC-F = 1.7 Hz), 123.9 (C, q, JC-F = 
283 Hz), 87.6 (C, q, JC-F = 30 Hz), 82.6 (C), 74.5 (CH), 27.1 (CH3), 21.0 (CH3); 
19F{1H} NMR (282 MHz, CDCl3) δ –80.4 (s, CF3); HRMS (ESI) m/z: [M+H]+ calcd for 
C16H19F3NO3+:  330.1312, found: 330.1316. cis-4b (minor diastereomer): colorless oil; 
[α]D25 +84.8 (c 1.09, CHCl3, 96% ee); 1H NMR (300 MHz, CDCl3) δ 7.57 (2H, d, J = 
8.1 Hz, Ar), 7.26 (2H, d, J = 8.1 Hz, Ar), 7.10 (1H, d, J = 2.1 Hz, N=CHO), 5.00 (1H, 
dd, J = 2.4, 0.9 Hz, CH), 2.38 (3H, s, CH3), 1.57 (9H, s, CH3); 13C{1H} NMR (75 MHz, 
CDCl3) δ 165.8 (C), 154.0 (CH), 139.7 (C), 132.6 (C), 129.4 (CH), 126.3 (CH), 123.0 
(C, q, JC-F = 283 Hz), 87.9 (C, q, JC-F = 30.1 Hz), 83.5 (C), 27.7 (CH3), 21.1 (CH3); 
19F{1H} NMR (282 MHz, CDCl3) δ –75.1 (s, CF3); HRMS (ESI) m/z: [M+H]+ calcd for 
C16H19F3NO3+:  330.1312, found: 330.1316. 
tert-Butyl (4S,5S)-5-(4-methoxyphenyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-
carboxylate (4c): Colorless oil (84.0 mg, >95% from 51.2 mg of 1c). HPLC (Chiralpak 
IC, hexane:iPrOH 90:10, 0.7 mL/min): trans-(4S, 5S)-4c (major diastereomer, 84%): 
major enantiomer, tr = 8.7 min, minor enantiomer, tr = 14.2 min; cis-4c (minor 
diastereomer, 77% ee): major enantiomer, tr = 16.8 min, minor enantiomer, tr = 20.9 
min; dr trans:cis = 63:37. trans-(4S, 5S)-4c (major diastereomer): [α]D25 +127.3 (c 0.82, 
CHCl3, 84% ee); 1H NMR (300 MHz, CDCl3) δ 7.39 (2H, d, J = 9.0, Ar), 7.18 (1H, d, J 
= 1.8 Hz, N=CHO), 6.89 (2H, d, J = 9.0 Hz, Ar), 5.04 (1H, d, J = 1.8 Hz, CH), 3.79 
(3H, s, CH3), 1.08 (9H, s, CH3); 13C{1H} NMR (75 MHz, CDCl3) δ 165.5 (C), 160.4 
(C), 155.3 (CH), 127.9 (CH, q, JC-F = 1.8 Hz), 123.9 (C, q, JC-F = 284 Hz), 122.9 (C), 
113.8 (CH), 87.5 (C, q, JC-F = 29 Hz), 82.7 (C), 74.5 (CH), 55.3 (CH3), 27.3 (CH3); 
19F{1H} NMR (282 MHz, CDCl3) δ –80.5 (s, CF3); HRMS (ESI) m/z: [M+H]+ calcd for 
C16H19F3NO4+: 346.1261, found: 346.1251. cis-4c (minor diastereomer): [α]D25 +47.1 (c 
0.75, CHCl3, 77% ee); 1H NMR (300 MHz, CDCl3) δ 7.61 (2H, d, J = 9.0 Hz, Ar), 7.10 
(1H, d, J = 2.4 Hz, N=CHO), 6.96 (2H, d, J = 9.0 Hz, Ar), 5.00 (1H, dd, J = 2.1, 0.6 Hz, 
CH), 3.83 (3H, s, CH3), 1.57 (9H, s, CH3); 13C{1H} NMR (75 MHz, CDCl3) δ 165.8 
(C), 160.5 (C), 154.0 (CH), 127.8 (CH), 127.4 (C), 123.0 (C, q, JC-F = 283 Hz), 114.1 
(CH), 87.8 (C, q, JC-F = 30 Hz), 83.5 (C), 77.4 (CH), 55.3 (CH3), 27.7 (CH3); 19F{1H} 
NMR (282 MHz, CDCl3) δ –75.4 (s, CF3); HRMS (ESI) m/z: [M+H]+ calcd for 
C16H19F3NO4+:  346.1261, found: 346.1251.  
tert-Butyl 5-(4-chlorophenyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate 
(4d): Colorless oil (103.4 mg, >95% from 62.0 mg of 1d). HPLC (Chiralpak IC, 
hexano:iPrOH 95:5, 1 mL/min): trans-(4S,5S)-4d (major diastereomer, 96% ee): major 
enantiomer, tr = 7.6 min, minor enantiomer, tr = 9.0 min; cis-4d (minor diastereomer, 
90% ee): major enantiomer, tr = 16.7 min, minor enantiomer, tr = 18.5 min; dr trans:cis 
= 53:47. trans-(4S,5S)-4d (major diastereomer): [α]D25 +81.7 (c 0.30, CHCl3, 96% ee); 
1H NMR (300 MHz, CDCl3) δ 7.43 (2H, d, J = 9.0 Hz, Ar), 7.37 (2H, d, J = 9.0 Hz, Ar), 
7.19 (1H, d, J = 2.0 Hz, N=CHO), 5.07 (1H, d, J = 2.0 Hz, CH), 1.08 (9H, s, CH3); 
13C{1H} NMR (75 MHz, CDCl3) δ 165.2 (C), 155.2 (CH), 135.8 (C), 129.5 (C), 128.7 
(CH), 128.0 (CH, q, JC-F = 1.9 Hz), 123.7 (C, q, JC-F = 283 Hz), 87.5 (C, q, JC-F = 30 
Hz), 83.1 (C), 74.6 (CH), 27.3 (CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –80.4 (s, 
CF3); HRMS (ESI) m/z: [M+H]+ calcd for C15H16ClF3NO3+: 350.0765, found: 350.0757. 
cis-4d (minor diastereomer): [α]D25 +48.6 (c 0.46, CHCl3, 90% ee); 1H NMR (300 MHz, 
CDCl3) δ 7.64 (2H, d, J = 9.0 Hz, Ar), 7.42 (2H, d, J = 9.0 Hz, Ar), 7.10 (1H, d, J = 2.1 
Hz, N=CHO), 4.96 (1H, dd, J = 2.1, 0.6 Hz, CH), 1.57 (9H, s, CH3); 13C{1H} NMR (75 
MHz, CDCl3) δ 165.4 (C), 153.9 (CH), 136.0 (C), 133.9 (C), 129.0 (CH), 127.9 (CH), 
122.8 (C, q, JC-F = 283 Hz), 87.5 (C, q, JC-F = 31 Hz), 83.9 (C), 77.4 (CH), 27.7 (CH3); 
19F{1H} NMR (282 MHz, CDCl3) δ –75.2 (s, CF3). HRMS (ESI) m/z: [M+H]+ calcd for 
C15H16ClF3NO3+: 350.0765, found: 350.0757. 
tert-Butyl 5-(m-tolyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (4e): 
Colorless oil (77.1 mg, 94% from 47.2 mg of 1e). HPLC (Chiralpak IC, hexane:iPrOH 
95:5, 1 mL/min): trans-(4S,5S)-4e (major diastereomer, 97% ee): major enantiomer, tr = 
5.6 min, minor enantiomer, tr = 6.7  min; cis-4e (minor  diastereomer, 87% ee): major 
enantiomer: tr = 10.0 min, minor enantiomer: tr = 14.4 min; dr trans:cis = 76:24. trans-
(4S,5S)-4e (major diastereomer): [α]D25 +166.8 (c 0.55, CHCl3, 97% ee); 1H NMR (300 
MHz, CDCl3) δ 7.27-7.25 (3H, m, Ar), 7.21-7.18 (2H, m, Ar, NCHO), 5.06 (1H, d, J = 
2.1 Hz, CH), 2.35 (3H, s, CH3), 1.04 (9H, s, CH3); 13C{1H} NMR (75 MHz, CDCl3) δ 
165.3 (C), 155.3 (CH), 138.0 (C), 130.9 (C), 130.1 (CH), 128.3 (CH), 126.9 (CH, q, JC-F 
= 2.0 Hz), 123.9 (C, q, JC-F = 283 Hz), 123.5 (CH, q, JC-F = 1.9 Hz), 87.6 (C, q, JC-F = 30 
Hz), 82.5 (C), 74.6 (CH), 27.1 (CH3), 21.4 (CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –
80.3 (s, CF3); HRMS (ESI) m/z: [M+H]+ calcd for C16H19F3NO3+:  330.1312, found: 
330.1308. cis-4e (minor diastereomer): [α]D25 +52.9 (c 0.98, CHCl3, 87% ee); 1H NMR 
(300 MHz, CDCl3) δ 7.51 (1H, s, Ar), 7.49 (1H, d, J = 9.0 Hz, Ar), 7.33 (1H, td, J = 7.5, 
0.6 Hz, Ar), 7.25 (1H, br d, J = 7.6 Hz, Ar), 7.11 (1H, d, J = 2.1 Hz, N=CHO), 5.01 
(1H, dd, J = 2.4, 0.9 Hz, CH), 2.40 (3H, s, CH3), 1.58 (9H, s, CH3); 13C{1H} NMR (75 
MHz, CDCl3) δ 165.7 (C), 154.0 (CH), 138.5 (C), 135.5 (C), 130.4 (CH), 128.6 (CH), 
126.9 (CH), 123.4 (CH), 123.0 (C, q, JC-F = 283 Hz), 87.9 (C, q, JC-F = 30 Hz), 83.5 
(CH), 77.4 (CH), 27.7 (CH3), 21.5 (CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –75.0 (s, 
CF3); HRMS (ESI) m/z: [M+H]+ calcd for C16H19F3NO3+:  330.1312, found: 330.1308. 
tert-Butyl 5-(3-methoxyphenyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate 
(4f): Colorless oil (72.7 mg, 84% from 51.1 mg of 1f). HPLC (Chiralpak IC, 
hexane:iPrOH 95:5, 1 mL/min): trans-(4S,5S)-4f (major diastereomer, 97% ee): major 
enantiomer, tr = 6.8 min, minor enantiomer, tr = 16.0 min, cis-4f (minor diastereomer, 
85% ee): major enantiomer, tr = 13.2 min, minor enantiomer, tr = 20.9 min; dr trans:cis 
= 72:28. trans-(4S,5S)-4f (major diastereomer): [α]D25 +164.7 (c 0.49, CHCl3, 97% ee); 
1H NMR (300 MHz, CDCl3) δ 7.28 (1H, td, J = 8.0, 0.6 Hz, Ar), 7.19 (1H, dd, J = 1.9, 
0.5 Hz, N=CHO), 7.06 (1H, m, Ar), 7.00 (1H, m, Ar), 6.91 (1H, ddd, J = 8.2, 2.5, 0.9 
Hz, Ar), 5.06 (1H, d, J = 1.9 Hz, CH), 3.80 (3H, s, CH3), 1.07 (9H, s, CH3); 13C{1H} 
NMR (75 MHz, CDCl3) δ 165.3 (C), 159.5 (C), 155.3 (CH), 132.3 (C), 129.5 (CH), 
123.8 (C, q, JC-F = 283 Hz), 118.6 (CH, q, JC-F = 2.0 Hz), 114.8 (CH), 112.5 (CH, q, JC-F 
= 1.8 Hz), 87.5 (C, q, JC-F = 30 Hz), 82.7 (C), 74.6 (CH), 55.3 (CH3), 27.2 (CH3); 
19F{1H} NMR (282 MHz, CDCl3) δ –80.4 (s, CF3); HRMS (ESI) m/z: [M+H]+ calcd for 
C16H19F3NO4+: 346.1261, found: 346.1260. cis-4f (minor diastereomer): [α]D25 +56.9 (c 
0.77, CHCl3, 85% ee); 1H NMR (300 MHz, CDCl3) δ 7.36 (1H, t, J = 7.8, Ar), 7.30-
7.24 (2H, m, Ar), 7.11 (1H, d, J = 2.1 Hz, N=CHO), 6.96 (1H, ddd, J = 8.1, 2.6, 1.2 Hz, 
Ar), 5.02 (1H, dd, J = 2.1, 0.6 Hz, CH), 3.84 (3H, s, CH3), 1.57 (9H, s, CH3); 13C{1H} 
NMR (75 MHz, CDCl3) δ 165.7 (C), 159.7 (C), 154.0 (CH), 132.2 (C), 129.8 (CH), 
122.9 (C, q, JC-F = 283 Hz), 118.5 (CH), 115.1 (CH), 112.2 (CH), 87.9 (C, q, JC-F = 30 
Hz), 83.6 (C), 77.4 (CH), 55.4 (CH3), 27.7 (CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –
74.9 (s, CF3); HRMS (ESI) m/z: [M+H]+ calc for C16H19F3NO4+ : 346.1261, found: 
346.1260. 
tert-Butyl 5-(3-bromophenyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate 
(4g): Colorless oil (95.7 mg, >95%, from 63.5 mg of 1g). HPLC (Chiralpak IC, 
hexane:iPrOH 95:5, 0.5 mL/min): trans-(4S,5S)-4g (major diastereomer, 90% ee): 
major enantiomer, tr = 10.8 min, minor enantiomer, tr = 12.7 min, cis-4g (minor 
diastereomer, 97% ee): major enantiomer, tr = 24.3 min, minor enantiomer, tr = 35.5 
min; dr trans:cis = 64:36. trans-(4S,5S)-4g (major diastereomer): [α]D25 +143.5 (c 0.52, 
CHCl3, 97% ee); 1H NMR (300 MHz, CDCl3) δ 7.63 (1H, bs, Ar), 7.52 (1H, ddd, J = 
7.9, 1.9, 1.0 Hz, Ar), 7.42 (1H, m, Ar), 7.26 (1H, td, J = 8.1, 0.6 Hz, Ar), 7.19 (1H, dd, J 
= 2.1, 0.6, N=CHO), 5.06 (1H, d, J = 2.0 Hz, CH), 1.10 (9H, s, CH3); 13C{1H} NMR 
(75 MHz, CDCl3) δ 165.1 (C), 155.1 (CH), 133.2 (C), 132.6 (CH), 130.0 (CH), 129.5 
(CH, q, JC-F = 1.8 Hz), 125.1 (CH, q, JC-F = 2.0 Hz), 123.6 (C, q, JC-F = 283 Hz), 122.6 
(C), 86.9 (C, q, JC-F = 30 Hz), 83.1 (C), 74.6 (CH), 27.2 (CH3); 19F{1H} NMR (282 
MHz, CDCl3) δ –80.3 (s, CF3); HRMS (ESI) m/z: [M+H]+ calcd for C15H16BrF3NO3+: 
394.0260, found: 394.0251. cis-4g (minor diastereomer): [α]D25 +42.7 (c 1.39, CHCl3, 
90% ee); 1H NMR (300 MHz, CDCl3) δ 7.89 (1H, bs, Ar), 7.64 (1H, br d, J = 8.0 Hz, 
Ar), 7.58 (1H, ddd, J = 8.0, 1.9, 1.0 Hz, Ar), 7.33 (1H, t, J = 7.9 Hz, Ar), 7.11 (1H, d, J 
= 2.3 Hz, N=CHO), 4.96 (1H, dd, J = 2.3, 0.9 Hz, CH), 1.58 (9H, s, CH3); 13C{1H} 
NMR (75 MHz, CDCl3) δ 165.2 (C), 153.9 (CH), 137.6 (C), 132.9 (CH), 130.3 (CH), 
129.7 (CH), 125.1 (CH), 122.8 (C), 122.7 (C, q, JC-F = 283 Hz), 87.2 (C, q, JC-F = 30.1 
Hz), 83.9 (C), 77.3 (CH), 27.7 (CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –75.1 (s, 
CF3); HRMS (ESI) m/z: [M+H]+ calcd for C15H16BrF3NO3+: 394.0260, found: 394.0251. 
tert-Butyl 5-(2-methoxyphenyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate 
(4h): White solid (69.0 mg, 80% from 51.0 mg of 1h). HPLC (Chiralpak IC, 
hexane:iPrOH 95:5, 1 mL/min): trans-(4S,5S)-4h (major diastereomer, 94% ee): major 
enantiomer, tr = 7.0 min, minor enantiomer, tr = 23.0 min; cis-4h (minor diastereomer, 
70% ee): major enantiomer, tr = 19.9 min, minor enantiomer, tr = 30.2 min; dr trans:cis 
= 94:6. trans-(4S,5S)-4h (major diastereomer): Mp: 76-79 ºC; [α]D25 +252.5 (c 0.78, 
CHCl3, 94% ee); 1H NMR (300 MHz, CDCl3) δ 7.57 (1H, dd, J = 7.8, 1.8 Hz, Ar), 7.37 
(1H, ddd, J = 8.4, 7.5, 1.8 Hz, Ar), 7.09 (1H, d, J = 2.0 Hz, N=CHO), 7.02 (1H, td, J = 
7.5, 1.0 Hz, Ar), 6.85 (1H, dd, J = 8.4, 1.2 Hz, Ar), 5.12 (1H, d, J = 2.0 Hz, CH), 3.76 
(3H, s, CH3), 1.12 (9H, s, CH3); 13C{1H} NMR (75 MHz, CDCl3) δ 165.6 (C), 155.7 
(C), 154.9 (CH), 130.6 (CH), 128.6 (CH), 123.9 (C, q, JC-F = 283 Hz), 120.6 (CH), 
120.5 (C), 110.4 (CH), 87.0 (C, q, JC-F = 30 Hz),  81.5 (C), 74.2 (CH), 54.7 (CH3), 27.3 
(CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –81.7 (s, CF3); HRMS (ESI) m/z: [M+H]+ 
calcd for C16H19F3NO4+:  346.1261, found: 346.1259. cis-4h (minor diastereomer): 
[α]D25 +70.7 (c 0.17, CHCl3, 70% ee); 1H NMR (300 MHz, CDCl3) δ 7.56 (1H, td, J = 
7.8, 1.5 Hz, Ar), 7.40 (1H, ddd, J = 8.2, 7.4, 1.7 Hz, Ar), 7.09 (1H, dd, J = 2.1, 0.6 Hz, 
N=CHO), 7.00 (1H, td, J = 7.5, 1.2 Hz, Ar), 6.98 (1H, dd, J = 7.2, 2.4 Hz, Ar), 5.23 
(1H, dd, J = 2.1, 0.9 Hz, CH), 3.89 (3H, s, CH3), 1.54 (9H, s, CH3); 13C{1H} NMR (75 
MHz, CDCl3) δ 166.2 (C), 156.6 (C), 153.6 (CH), 131.3 (CH), 128.2 (CH), 123.3 (C, q, 
JC-F = 283), 123.0 (C), 120.6 (CH), 111.9 (CH), 87.6 (C, q, JC-F = 32 Hz), 82.4 (C), 75.5 
(CH), 55.2 (CH3), 27.8 (CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –72.4 (s, CF3); 
HRMS (ESI) m/z: [M+H]+ calcd for C16H19F3NO4+: 346.1261, found: 346.1259.  
tert-Butyl 5-(2-bromophenyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate 
(4i): White solid (122.8 mg, >95% from 79.0 mg of 1i). HPLC (Chiralpak IC, 
hexane:iPrOH 95:5, 1 mL/min): trans-(4S,5S)-4i (major diastereomer, 91% ee): major 
enantiomer, tr = 5.8 min, minor enantiomer, tr = 9.3 min; dr trans:cis > 99:1. trans-
(4S,5S)-4i (major diastereomer): Mp: 96-99 ºC; [α]D25 +190.2 (c 0.54, CHCl3, 91% ee); 
(two possible rotamers are observed) 1H NMR (300 MHz, CDCl3) δ 7.74 (1H, 
unresolved d, J = 7.4 Hz, Ar), 7.60 (1H, dd, J = 7.8, 1.2 Hz, Ar), 7.38 (1H, ddd, J = 7.9, 
7.3, 1.3 Hz, Ar), 7.24 (1H, ddd, J = 8.0, 7.4, 1.7 Hz, Ar), 7.13 (1H, d, J = 1.8 Hz, 
N=CHO), 5.35 (1H, bs, CH), 1.22 (9H, s, CH3); 13C{1H} NMR (75 MHz, CDCl3) δ 
165.3 (C), 154.8 (CH), 136.1 (C), 134.5 (CH), 130.6 (CH), 130.3 (CH), 127.4 (CH), 
123.7 (C, q, J = 286 Hz), 120.8 (C), 88.5 (C, q, JC-F = 30 Hz), 82.6 (CH), 74.0 (CH), 
27.2 (CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –79.0 (s, CF3); HRMS (ESI) m/z: 
[M+H]+ calcd for C15H16BrF3NO3+: 394.0260, found: 394.0251. For the X-ray structure 
of 4i see Figure S1 in the SI. 
tert-Butyl 5-(3,4-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate 
(4j): Colorless oil (95.1 mg, >95% from 61.0 mg of 1j). HPLC (Chiralpak IC, 
hexane:iPrOH 95:5, 1 mL/min): trans-(4S,5S)-4j (major diastereomer, 94% ee): major 
enantiomer, tr = 6.7 min, minor enantiomer, tr = 7.5 min; cis-4j (minor diastereomer, 
85% ee): major enantiomer, tr = 14.9 min, minor enantiomer, tr = 17.2 min; dr trans:cis 
= 53:47. trans-(4S,5S)-4j (major diastereomer): [α]D25 +131.8 (c 0.48, CHCl3, 94% ee); 
1H NMR (300 MHz, CDCl3) δ 7.57 (1H, d, J = 1.8 Hz, Ar), 7.47 (1H, d, J = 8.4 Hz, Ar), 
7.33 (1H, ddd, J = 8.4, 2.2, 0.8 Hz, Ar), 7.19 (1H, d, J = 2.1 Hz, N=CHO), 5.06 (1H, d, 
J = 2.1 Hz, CH), 1.13 (9H, s, CH3); 13C{1H} NMR (75 MHz, CDCl3) δ 165.0 (C), 155.0 
(CH), 134.2 (C), 132.9 (C), 131.1 (C), 130.5 (CH), 128.7 (CH, q, JC-F = 1.9 Hz), 125.8 
(CH, q, JC-F = 1.7 Hz), 123.5 (C, q, JC-F = 283 Hz), 86.5 (C, q, JC-F = 30 Hz), 83.4 (C), 
74.6 (CH), 27.3 (CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –80.4 (s, CF3); HRMS 
(ESI) m/z: [M+H]+ calcd for C15H15Cl2F3NO3+: 384.0376, found: 384.0371. cis-4j 
(minor diastereomer): [α]D25 +68.2 (c 0.45, CHCl3, 85% ee); 1H NMR (300 MHz, 
CDCl3) δ 7.84 (1H, brs, Ar), 7.60-7.50 (2H, m, Ar), 7.11 (1H, d, J = 2.4 Hz, N=CHO), 
4.94 (1H, dd, J = 2.4, 0.9 Hz, CH), 1.58 (9H, s, CH3); 13C{1H} NMR (75 MHz, CDCl3) 
165.1 (C), 153.8 (CH), 135.4 (C), 134.4 (C), 133.3 (C), 130.9 (CH), 128.7 (CH), 125.8 
(CH), 122.6 (C, q, JC-F = 283 Hz), 86.9 (C, q, JC-F = 30.8 Hz), 84.1 (CH), 77.4 (CH), 
27.7 (CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –75.2 (s, CF3); HRMS (ESI) m/z: 
[M+H]+ calcd for C15H15Cl2F3NO3+: 384.0376, found: 384.0371.  
tert-Butyl 5-(thiophen-2-yl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (4k): 
Yellow oil (87.1 mg, >95% from 48.9 mg of 1k). HPLC (Lux Cellulose-4, 
hexane:iPrOH 98:2, 1 mL/min): trans-(4S,5S)-4k (major diastereomer, 97% ee): major 
enantiomer, tr = 7.7 min, minor enantiomer, tr = 9.3 min, cis-4k (minor diastereomer, 
91% ee): major enantiomer, tr = 15.3 min, minor enantiomer, tr = 17.7 min; dr trans:cis 
= 62:38. trans-(4S,5S)-4k (major diastereomer): [α]D25 +127.4 (c 0.49, CHCl3, 97% ee); 
1H NMR (300 MHz, CDCl3) δ 7.34 (1H, dd, J = 5.1, 1.2 Hz, Ar), 7.16-7.11 (2H, m, Ar, 
N=CHO), 7.02 (1H, dd, J = 5.1, 3.6 Hz, Ar), 5.06 (1H, d, J = 2.1 Hz, CH), 1.14 (9H, s, 
CH3). 13C{1H} NMR (75 MHz, CDCl3) δ 165.0 (C), 154.6 (CH), 132.8 (C), 127.5 (CH), 
127.3 (CH, q, JC-F = 2.0 Hz, Ar), 126.5 (CH), 123.3 (C, q, JC-F = 283 Hz), 86.3 (C, q, JC-
F = 32 Hz), 82.9 (C), 75.0 (CH), 27.3 (CH3). 19F{1H} NMR (282 MHz, CDCl3) δ –81.8 
(s, CF3); HRMS (ESI) m/z: [M+H]+ calcd for C13H15F3NO3S+: 322.0719, found 
322.0713. cis-4k (minor diastereomer): [α]D25 +164.7 (c 0.49, CHCl3, 91% ee); 1H 
NMR (300 MHz, CDCl3) δ 7.41 (1H, dd, J = 5.1, 1.3 Hz, Ar), 7.39-7.38 (1H, m, Ar), 
7.09 (1H, d, J = 2.4 Hz, N=CHO), 7.08 (1H, t, J = 3.7 Hz, Ar), 5.08 (1H, dd, J = 2.4, 0.9 
Hz, CH), 1.55 (9H, s, CH3); 13C{1H} NMR (75 MHz, CDCl3) δ 165.0 (C), 153.9 (CH), 
137.7 (C), 127.4 (CH), 127.3 (CH), 127.2 (CH), 122.5 (C, q, JC-F = 283 Hz), 86.4 (C, q, 
JC-F = 32 Hz), 83.7 (C), 78.2 (CH), 27.7 (CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –
75.5 (s, CF3); HRMS (ESI) m/z: [M+H]+ calcd for C13H15F3NO3S++ 322.0719, found  
322.0713.  
tert-Butyl 5-phenethyl-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (4l): 
Yellow oil (71.2 mg, 83% from 50.0 mg of 1l). HPLC (Chiralpak AY-H, hexane:iPrOH 
95:5, 1 mL/min): trans-(4S,5S)-4l (major diastereomer, 84% ee): minor enantiomer, tr = 
5.2 min, major enantiomer, tr = 7.0 min; cis-4l (minor diastereomer, 87% ee): minor 
enantiomer, tr = 8.7 min, major enantiomer, tr = 12.6 min; dr trans:cis = 72:28. trans-
(4S,5S)-4l (major diastereomer): [α]D25 +51.2 (c 0.86, CHCl3, 84% ee); 1H NMR 
(300MHz, CDCl3) δ 1H NMR (300MHz, CDCl3) δ 7.30-7.26 (2H, m, Ar), 7.22-7.19 
(1H, m, Ar), 7.17-7.13 (2H, m, Ar), 7.00 (1H, d, J = 2.2 Hz, N=CHO), 4.88 (1H, d, J = 
2.3 Hz, CH), 2.75 (2H, t, J = 8.9 Hz, CH2), 2.38-2.27 (1H, m, CH), 2.22-2.11 (1H, m, 
CH), 1.47 (9H, s, CH3); 13C{1H} NMR (75 MHz, CDCl3) δ 166.5 (C), 154.8 (CH), 
140.1 (C), 128.5 (CH), 128.0 (CH), 126.4 (CH), 124.3 (C, q, JC-F = 282 Hz), 85.7 (C, q, 
JC-F = 30 Hz),  83.4 (C), 72.1 (CH), 31.3 (CH2), 28.6 (CH2), 27.9 (CH3); 19F{1H} NMR 
(282 MHz, CDCl3) δ –79.9 (s, CF3); HRMS (ESI) m/z: [M+H]+ calcd for 
C17H21F3NO3+: 344.1468, found: 344.1472. cis-4l (minor diastereomer): [α]D25 +52.1 (c 
0.59, CHCl3, 87% ee); 1H NMR (300 MHz, CDCl3) δ 7.35-7.29 (2H, m, Ar), 7.26-7.17 
(3H, m, Ar), 7.01 (1H, d, J = 2.2 Hz, N=CHO), 4.71 (1H, d, J = 1.7 Hz, CH), 2.81-2.66 
(2H, m, CH2), 2.46-2.36 (1H, m, CH), 2.30-2.17 (1H, m, CH), 1.50 (9H, s, CH3); 
13C{1H} NMR (75 MHz, CDCl3) δ 165.7 (C), 154.7 (CH), 139.7 (C), 128.7 (CH), 128.2 
(CH), 126.6 (CH), 123.7 (C, q, JC-F = 284.3 Hz), 86.9 (C, q, JC-F = 29 Hz), 83.2 (CH), 
73.2 (C), 35.7 (CH2), 28.4 (CH2), 27.7 (CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –74.6 
(s, CF3). HRMS (ESI) m/z: [M+H]+ calcd for C17H21F3NO3+: 344.1468, found: 
344.1472. 
General procedure for the enantioselective formal [3+2] cycloaddition reaction 
with methyl 2-isocyano-2-phenylacetate. 
Squaramide VIII (6.8 mg, 0.0125 mmol) and silver oxide (1.5 mg, 0.0063 mmol) were 
introduced in a round bottom flask followed by MTBE (2 mL) and 
trifluoroacetophenone 1 (0.25 mmol). The flask was closed with a stopper and 
introduced in a bath at −20 ºC. After 5 min, methyl 2-isocyano-2-phenylacetate (2c, 40 
µL, 0.33 mmol) was added and the mixture was stirred at −20 ºC until consumption of 
the trifluoroacetophenone 1 (TLC). After this time, the reaction mixture was filtered 
through a short pad of silica gel and concentred under reduced pressure. Compounds 5 
were quickly hydrolyzed during slow column chromatography, so separation of both 
diastereomers by this procedure was not possible. 
The racemic product was obtained using a similar procedure using the catalyst 3-((3,5-
bis(trifluoromethyl)phenyl)amino)-4-((3-(dimethylamino)propyl)amino)cyclobut-3-ene-
1,2-dione and silver oxide. 
Methyl 4,5-diphenyl-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (5a): Yellow 
oil (76.9 mg, 89% from 43.0 mg of 1a). HPLC (Chiralpak IC, hexane:iPrOH 95:5, 1 
mL/min): trans-5a (minor diastereomer): major enantiomer, tr = 8.4 min, minor 
enantiomer, tr = 6.7 min; cis-5a (major diastereomer, 90% ee): major enantiomer, tr = 
18.3 min, minor enantiomer, tr = 12.3 min; dr trans:cis = 15:85. cis-5a (major 
diastereomer): [α]D25 –5.3 (c 1.0, CHCl3, for the diastereomer mixture); 1H NMR (300 
MHz, CDCl3) δ 7.46-7.41 (3H, m, Ar), 7.43 (1H, s, N=CHO), 7.15-7.08 (2H, s, Ar), 
7.03 (5H, s, Ar), 3.98 (3H, s, CH3); 13C{1H} NMR (75 MHz, CDCl3) δ 168.6 (C), 153.2 
(CH), 134.4 (C), 130.6 (C), 128.7 (CH), 128.3 (CH), 127.8 (CH), 127.6 (CH), 127.51 
(CH), 127.46 (CH), 123.7 (C, q, JC-F = 283 Hz), 92.6 (C, q, JC-F = 29 Hz), 86.1 (C), 53.4 
(CH3); 19F{1H} NMR (282 MHz, CDCl3) δ -72.9 (s, CF3); HRMS (ESI) m/z: [M+H]+ 
calcd for C18H15F3NO3+: 350.0999, found: 350.0995. trans-5a (minor diastereomer): 
representative signals taken from the NMR spectra of the diastereomer mixture, 1H 
NMR (300 MHz, CDCl3) δ 7.92 (2H, dd, J = 8.1, 3.0 Hz, Ar), 7.72 (2H, dd, J = 8.0, 3.0 
Hz, Ar), 7.50-7.35 (7H, m, Ar, N=CHO), 3.14 (3H, s, CH3); 19F{1H} NMR (282 MHz, 
CDCl3) δ –72.3 (s, CF3).  
Methyl 5-(4-methoxyphenyl)-4-phenyl-5-(trifluoromethyl)-4,5-dihydrooxazole-4-
carboxylate (5c): Yellow oil (40.3 mg, 42% from 51.0 mg of 1c). HPLC (Chiralpak IC, 
hexane:iPrOH 95:5, 1 mL/min): trans-5c (minor diastereomer): major enantiomer, tr = 
8.6 min, minor enantiomer, tr = 12.1 min; cis-5c (major diastereomer, 89% ee): major 
enantiomer, tr = 25.6 min, minor enantiomer tr = 18.5 min; dr trans:cis = 21:79. cis-5c 
(major diastereomer): [α]D25 –12.3 (c 1.7, CHCl3, for the diastereomer mixture); 1H 
NMR (300 MHz, CDCl3) δ 7.41 (1H, s, N=CHO), 7.34 (2H, d, J = 8.4 Hz, Ar), 7.05-
7.03 (5H, s, Ar), 6.62 (2H, d, J = 9.0 Hz, Ar), 3.97 (3H, s, CH3), 3.68 (3H, s, CH3); 
13C{1H} NMR (75 MHz, CDCl3) δ 168.7 (C), 159.6 (C), 153.2 (CH), 134.6 (C), 129.7 
(C), 129.0 (CH), 128.3 (C), 127.8 (CH), 127.5 (CH), 123.7 (C, q, JC-F = 283 Hz), 112.9 
(CH), 92.6 (C, q, JC-F = 28.5 Hz), 86.1 (C), 55.0 (CH3), 53.3 (CH3); 19F{1H} NMR (282 
MHz, CDCl3) δ –73.28 (s, CF3); HRMS (ESI) m/z: [M+H]+ calcd for C19H17F3NO4+: 
380.1104, found: 380.1106. trans-5c (minor diastereomer): representative signals taken 
from the NMR spectra of the diastereomer mixture, 1H NMR (300 MHz, CDCl3) δ 7.93-
7.90 (2H, m, Ar), 7.62 (2H, d, J = 8.7 Hz, Ar), 7.44 (1H, s, N=CHO), 6.96 (2H, d, J = 
9.0 Hz, Ar), 3.84 (3H, s, CH3), 3.19 (3H, s, CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –
72.6 (s, CF3). 
Methyl 5-(4-chlorophenyl)-4-phenyl-5-(trifluoromethyl)-4,5-dihydrooxazole-4-
carboxylate (5d): Yellow oil (95.9 mg, >95% from 53.0 mg of 1d). HPLC (Chiralpak 
IC, hexane:iPrOH 95:5, 1 mL/min): trans-5d (minor diastereomer): major enantiomer, tr 
= 8.0 min, minor enantiomer, tr = 6.0 min; cis-5d (major diastereomer, 89% ee): major 
enantiomer, tr = 15.7 min, minor enantiomer tr = 12.0 min; dr trans:cis = 10:90. cis-5d 
(major diastereomer): [α]D25 –8.0 (c 0.93, CHCl3, for the diastereomer mixture); 1H 
NMR (300 MHz, CDCl3) δ 7.43 (1H, s, N=CHO), 7.39 (2H, d, J = 8.7 Hz, Ar), 7.13-
6.96 (7H, m, Ar), 3.98 (3H, s, CH3); 13C{1H} NMR (75 MHz, CDCl3) δ 168.5 (C), 
153.1 (CH), 134.9 (C), 134.0 (C), 129.5 (C), 129.1 (CH), 128.6 (CH), 128.0 (CH), 
127.8 (CH), 127.3 (CH), 123.5 (C, q, JC-F = 283 Hz), 92.2 (C, q, JC-F = 29 Hz),  86.1 
(C), 53.5 (CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –73.2 (s, CF3); HRMS (ESI) m/z: 
[M+H]+ calcd for C18H14ClF3NO3+: 384.0609, found: 384.0609. trans-5d (minor 
diastereomer): representative signals taken from the NMR spectra of the diastereomer 
mixture, 1H NMR (300 MHz, CDCl3) δ 8.00 (2H, d, J = 8.1 Hz, Ar), 7.52 (2H, d, J = 
9.0 Hz, Ar), 3.2 (3H, s, CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –71.5 (s, CF3). 
Methyl 5-(4-bromophenyl)-4-phenyl-5-(trifluoromethyl)-4,5-dihydrooxazole-4-
carboxylate (5n): Yellow oil (87.5 mg, 82% from 63.1 mg of 5n). HPLC (Chiralpak IC, 
hexane:iPrOH 90:10, 1 mL/min): trans-5n (minor diastereomer): both enantiomers 3.6 
min; cis-5n (major diastereomer, 89% ee): major enantiomer, tr = 10.5 min, minor 
enantiomer, tr = 8.6 min; dr trans:cis = 13:87. cis-5n (major diastereomer): [α]D25 –12.0 
(c 0.82, CHCl3, 89% ee, for the diastereomer mixture); 1H NMR (300 MHz, CDCl3) δ 
7.37 (1H, s, N=CHO), 7.26 (2H, d, J = 8.5 Hz, Ar), 7.17 (2H, d, J = 9.0 Hz, Ar), 7.04-
6.90 (5H, m, Ar), 3.91 (3H, s, CH3); 13C{1H} NMR (75 MHz, CDCl3) δ 168.5 (C), 
153.1 (CH), 134.0 (C), 130.8 (CH), 129.7 (CH), 129.4 (CH), 128.7 (CH), 128.1 (CH), 
127.3 (CH), 123.4 (C, q, JC-F = 283 Hz), 123.3 (C), 92.3 (C, q, JC-F = 29 Hz), 86.1 (C), 
53.5 (CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –73.1 (s, CF3); HRMS (ESI) m/z: 
[M+H]+ calcd for  C18H14BrF3NO3+: 428.0104, found: 428.0107. trans-5n (minor 
diastereomer): representative signals taken from the NMR spectra of the diastereomer 
mixture, 1H NMR (300 MHz, CDCl3) δ 7.81-7.78 (2H, m, Ar), 7.37 (1H, s, N=CHO), 
3.14 (3H, s, CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –72.4 (s, CF3). 
Methyl 4-phenyl-5-(m-tolyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (5e): 
Yellow oil (78.5 mg, 86% from 47.0 mg of 1e). HPLC (Chiralpak IC, hexane:iPrOH 
90:0, 1 mL/min): cis-5e (major diastereomer, 90% ee): major enantiomer, tr = 11.4 min, 
minor enantiomer, tr = 8.5 min; dr trans:cis = 1:99. cis-5e (major diastereomer): [α]D25 –
6.5 (c 0.69, CHCl3, 90% ee); 1H NMR (300 MHz, CDCl3) δ 7.44 (1H, s, N=CHO), 
7.26-7.22 (2H, unresolved m, Ar), 7.04 (5H, s, Ar), 6.98 (1H, t, J = 7.7 Hz, Ar), 6.91 
(1H, br d, J = 7.5 Hz, Ar), 3.97 (3H, s, CH3), 2.17 (3H, s, CH3); 13C{1H} NMR (75 
MHz, CDCl3) δ 168.7 (C), 153.3 (CH), 137.1 (C), 134.4 (C), 130.5 (C), 129.4 (CH), 
128.3 (CH), 127.7 (CH), 127.5 (CH), 127.4 (CH), 124.6 (C), 123.7 (C, q, JC-F = 283 
Hz), 92.6 (C, q, JC-F = 29 Hz), 86.1 (C), 53.3 (CH3), 21.2 (CH3); 19F{1H} NMR (282 
MHz, CDCl3) δ –72.8 (s, CF3); HRMS (ESI) m/z: [M+H]+ calcd for C19H17F3NO3+: 
364.1155, found: 364.1157.   
Methyl 5-(3-methoxyphenyl)-4-phenyl-5-(trifluoromethyl)-4,5-dihydrooxazole-4-
carboxylate (5f): Yellow oil (75.4 mg, 86% from 51.0 mg of 1f). HPLC (Chiralpak IC, 
hexane:iPrOH 95:5, 1 mL/min): trans-5f (minor diastereomer): major enantiomer, tr = 
7.5 min, minor enantiomer, tr = 10.1 min, cis-5f (major diastereomer, 89%): major 
enantiomer, tr = 19.6 min, minor enantiomer, tr = 12.5 min; dr trans:cis = 15:85. cis-5f 
(major diastereomer): [α]D25 +5.40 (c 0.72, CHCl3, for the diastereomer mixture); 1H 
NMR (300 MHz, CDCl3) δ 7.43 (1H, s, N=CHO), 7.10-6.90 (8H, m, Ar), 6.65 (1H, ddd, 
J = 7.4, 2.6, 1.7 Hz, Ar), 3.98 (3H, s, CH3), 3.65 (3H, s, CH3); 13C{1H} NMR (75 MHz, 
CDCl3) δ 168.6 (C), 158.7 (C), 153.2 (CH), 134.4 (C), 131.9 (C), 128.7 (CH), 128.4 
(CH), 127.8 (CH), 127.4 (CH), 123.6 (C, q, JC-F = 287 Hz), 120.0 (CH), 114.6 (CH), 
113.4 (C), 92.4 (C, q, JC-F = 28 Hz), 86.1 (C), 55.1 (CH3), 53.4 (CH3); 19F{1H} NMR 
(282 MHz, CDCl3) δ –72.9 (s, CF3); HRMS (ESI) m/z: [M+H]+ calcd for 
C19H17F3NO4+: 380.1104, found 380.1107. trans-5f (minor diastereomer): 
representative signals taken from the NMR spectra of the diastereomer mixture, 1H 
NMR (300 MHz, CDCl3) δ 7.93-7.90 (1H, m, Ar), 7.45 (1H, s, N=CHO), 3.85 (3H, s, 
CH3), 3.18 (3H, s, CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –72.3 (s, CF3). 
Methyl 5-(3-bromophenyl)-4-phenyl-5-(trifluoromethyl)-4,5-dihydrooxazole-4-
carboxylate (5g): Yellow oil (86.8 mg, 81% from 63.0 mg of 1g). HPLC (Chiralpak IC, 
hexane:iPrOH 90:10, 1 mL/min): trans-5g (minor diastereomer): major enantiomer, tr = 
7.0 min, minor enantiomer, tr = 5.7 min; cis-5g (major diastereomer, 88% ee): minor 
enantiomer, tr = 10.1 min, major enantiomer, tr = 14.3 min; dr trans:cis = 2:98. cis-5g 
(major diastereomer): [α]D25 –15.4 (c 0.92, CHCl3,  for the diastereomer mixture); 1H 
NMR (300 MHz, CDCl3) 7.51 (1H, s, Ar), 7.36 (1H, s, N=CHO), 7.32 (1H, br d, J = 8.0 
Hz, Ar), 7.17 (1H, d, J = 9.0 Hz), 7.03-6.92 (5H, m, Ar), 6.88 (1H, t, J = 8.1 Hz, Ar), 
3.91 (3H, s, CH3); 13C{1H} NMR (75 MHz, CDCl3) δ 168.4 (C), 153.1 (CH), 133.8 (C), 
132.8 (C), 131.9 (CH), 130.6 (br, CH), 129.0 (CH), 128.7 (CH), 128.0 (CH), 127.3 
(CH), 126.4 (CH), 123.4 (C, q, JC-F = 283 Hz), 121.7 (C), 92.0 (C, q, JC-F = 29 Hz), 86.2 
(C), 53.5 (CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –72.8 (s, CF3); HRMS (ESI) m/z: 
[M+H]+ calcd for C18H14BrF3NO3+:  428.0104, found: 428.0107. trans-5g (minor 
diastereomer): representative signals taken from the NMR spectra of the diastereomer 
mixture, 1H NMR (300 MHz, CDCl3) δ 8.12 (1H, s, Ar), 7.93 (1H, d, J = 9.2 Hz, Ar), 
7.80-7.70 (2H, m, Ar), 3.15 (3H, s, CH3);  19F{1H} NMR (282 MHz, CDCl3) δ –71.5 (s, 
CF3). 
Methyl (2S,3S)-4,4,4-trifluoro-2-formamido-3-hydroxy-3-phenylbutanoate (6a): 6 M 
Aqueous HCl (6 drops) was added to a solution of compound 3a (54.0 mg, 0.20 mmol) 
in THF (1 mL). The reaction mixture was stirred at rt for 24 h. The mixture was basified 
with saturated aqueous NaHCO3 (1 mL), water was added (10 mL), extracted with 
EtOAc (3 × 20 mL), washed with brine (20 mL) and dried over MgSO4. Removal of the 
solvent under reduced pressure afforded compound 6a as a colorless oil (58.0 mg, 
95%). HPLC (Chiracel OD-H, hexane:iPrOH 90:10, 1 mL/min): trans-6a (major 
diastereomer, 88% ee); major enantiomer, tr = 14.0 min, minor enantiomer, tr = 11.0 
min; cis-6a (minor diastereomer), major enantiomer, tr = 8.5 min, minor enantiomer, tr 
= 7.9 min; dr  trans:cis = 96:4. trans-6a (major diastereomer): [α]D25 –23.6 (c 0.68, 
CHCl3, for the diastereomer mixture); 1H NMR (300 MHz, CDCl3) δ 8.24 (1H, dd, J = 
1.2, 0.7 Hz, CHO), 7.59-7.57 (2H, m, Ar), 7.42-7.40 (3H, m, Ar), 6.79 (1H, d, J = 9.0 
Hz, NH), 5.57 (1H, dd, J = 9.0, 0.6 Hz, CH), 4.68 (1H, bs, OH), 3.47 (3H, s, CH3); 
13C{1H} NMR (75 MHz, CDCl3) δ 170.0 (C), 160.7 (CH), 134.4 (C), 129.6 (CH), 128.6 
(CH), 126.1 (CH), 123.9 (C, q, JC-F = 283 MHz), 78.20 (C, q, JC-F = 30 Hz), 53.5 (CH), 
52.9 (CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –75.8 (s, CF3); HRMS (ESI) m/z: 
[M+H]+ calcd for C12H13F3NO4+: 292.0791, found: 292.0798. cis-6a (minor 
diastereomer): representative signals taken from the NMR spectra of the diastereomer 
mixture, 1H NMR (300 MHz, CDCl3) δ 4.85 (d, J = 10.5 Hz, CH), 3.54 (3H, s, CH3); 
19F{1H} NMR (282 MHz, CDCl3) δ –76.4 (s, CF3). 
Methyl (2S,3S)-3-(3-bromophenyl)-4,4,4-trifluoro-2-formamido-3-hydroxybutanoate 
(6g): Following the same procedure for the synthesis of compound 6a, from compound 
3g (42.3 mg, 0.12 mmol) was obtained formamide 6g as colorless oil (42.6 mg, 95%). 
HPLC (Chiralpak AY-H, hexane:iPrOH 95:5, 1 mL/min): trans-6g (major 
diastereomer, 91% ee): major enantiomer, tr = 21.9 min, minor enantiomer, tr = 29.6 
min; cis-6g (minor diastereomer): major enantiomer, tr = 10.9 min, minor enantiomer, tr 
= 8.7 min; dr trans:cis = 83:17. trans-6g (major diastereomer): [α]D25 +5.41 (c 0.72, 
CHCl3, for the diastereomer mixture); 1H NMR (300 MHz, CDCl3) δ 8.25 (1H, dd, J = 
1.0, 0.7 Hz, CHO), 7.77 (1H, bs, Ar), 7.57-7.50 (2H, m, Ar), 7.29 (1H, t, J = 8.0 Hz, 
Ar), 6.75 (1H, d, J = 8.8 Hz, NH), 5.52 (1H, d, J = 9.0 Hz, CH), 4.85 (1H, bs, OH), 3.55 
(3H, s, CH3); 13C{1H} NMR (75 MHz, CDCl3) δ 169.7 (C), 160.8 (CH), 136.8 (C), 
132.7 (CH), 130.0 (CH), 129.5 (CH), 124.9 (CH), 123.7 (C, q, JC-F = 285 MHz), 122.9 
(C), 77.8 (C, q, JC-F = 29 MHz), 53.6 (CH), 53.1 (CH3); 19F{1H} NMR (282 MHz, 
CDCl3) δ –75.2 (s, CF3). HRMS (ESI) m/z: [M+H]+ calcd for C12H12BrF3NO4+: 
369.9896, found: 369.9883. cis-6g (minor diastereomer): 1H NMR (300 MHz, CDCl3) 
representative signals taken from the NMR spectra of the diastereomer mixture, δ 7.93 
(1H, s, CHO), 7.82 (1H, t, J = 1.7 Hz, Ar), 6.16 (1H, d, J = 9.0 Hz, NH), 5.42 (1H, d, J 
= 9.0 Hz, CH), 3.87 (3H, s, CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –71.5 (s, CF3). 
Methyl (2S,3S)-2-amino-4,4,4-trifluoro-3-hydroxy-3-phenylbutanoate (7a): 6M 
Aqueous HCl (6 drops) was added to a solution of compound 3a (28.6 mg, 0.11 mmol) 
in MeOH (1 mL). The reaction mixture was stirred at rt for 24 h. The mixture was 
basified with saturated aqueous NaHCO3 (1 mL), water was added (10 mL), extracted 
with EtOAc (3 × 20 mL), washed with brine (20 mL) and dried over MgSO4. Removal 
of the solvent under reduced pressure aforded compound 7a as colorless oil (27.6 mg, 
95%). HPLC (Chiralpak AY-H, hexane:iPrOH 95:5, 1 mL/min): trans-7a (major 
diastereomer, 90% ee): major enantiomer, tr = 15.8 min, minor enantiomer, tr = 17.3 
min; cis-7a (minor diastereomer): major enantiomer, tr = 11.8 min; minor enantiomer, tr 
= 9.6 min; dr trans:cis 92:8. trans-7a (major diastereomer): [α]D25 +47.9 (c 1.23, CHCl3, 
for the diastereomer mixture); 1H NMR (300 MHz, CDCl3) δ 7.61-7.54 (2H, m, Ar), 
7.38-7.35 (3H, m, Ar), 4.33 (1H, s, CH), 3.29 (3H, s, CH3); 13C{1H} NMR (75 MHz, 
CDCl3) δ 171.3 (C), 135.1 (C), 128.8 (CH), 128.0 (CH),  126.3 (CH, q, JC-F = 2.0 Hz), 
125.2 (C, q, JC-F = 283 Hz), 76.4 (C, q, JC-F = 27 Hz), 57.3 (CH), 52.0 (CH3); 19F{1H} 
NMR (282 MHz, CDCl3) δ –75.9 (s, CF3). HRMS (ESI) m/z: [M+H]+ calcd for 
C11H13F3NO3+: 264.0842, found: 264.0851. cis-7a (minor diastereomer): 1H NMR (300 
MHz, CDCl3) representative signals taken from the NMR spectra of the diastereomer 
mixture, δ 7.65-7.60 (2H, m, Ar), 7.45-7.31 (3H, m, Ar), 4.07 (1H, s, CH), 3.83 (3H, s, 
CH3); 13C{1H} NMR (75 MHz, CDCl3) δ  56.5(CH), 52.9 (CH3); 19F{1H} NMR (282 
MHz, CDCl3) δ –75.0 (s, CF3). 
Methyl 2-amino-3-(3-bromophenyl)-4,4,4-trifluoro-3-hydroxybutanoate (7g): Following 
the same procedure for the synthesis of compound 7a, from compound 3g (22.7 mg, 
0.064 mmol), was obtained 7g (21.0 mg, 95%). HPLC (Chiralpak AD-H, hexane:iPrOH 
98:2, 0.7 mL/min): trans-7g: (major diastereomer, 92% ee): major enantiomer, tr = 36.5 
min, minor enantiomer, tr = 34.9 min. cis-7g (minor diastereomer): major enantiomer, tr 
= 32.8 min, minor enantiomer, tr = 28.9 min; dr trans:cis 93:7. trans-7g: (major 
diastereomer): [α]D25 +49.1 (c 0.68, CHCl3, for the diastereomer mixture); 1H NMR 
(300 MHz, CDCl3) δ 7.77 (1H, t, J = 1.9 Hz, Ar), 7.55-7.48 (2H, m, Ar), 7.24 (1H, t, J = 
7.9 Hz, Ar), 4.32 (1H, s, CH), 3.35 (3H, s, CH3); 13C{1H} NMR (75 MHz, CDCl3) δ 
170.8 (C), 137.3 (C), 132.0 (CH), 129.7 (CH, q, JC-F = 1.6 Hz), 129.5 (CH), 125.1 (CH, 
q, JC-F = 1.6 Hz), 124.9 (C, q, JC-F = 289 MHz), 75.9 (C, q, JC-F = 27 Hz), 57.1 (CH), 
52.2 (CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –75.6 (s, CF3). HRMS (ESI) m/z: 
[M+H]+ calcd for C11H12BrF3NO3+: 341.9947, found: 341.9948. For the X-ray structure 
of trans-7g see Figure S2 in the SI. cis-7g (minor diastereomer): representative signals 
taken from the NMR spectra of the diastereomer mixture, 1H NMR (300 MHz, CDCl3) 
δ 7.82 (1H, br s, Ar), 7.56-7.44 (2H, m, Ar), 7.31 (1H, t, J = 8.0 Hz, Ar), 4.00 (1H, s, 
CH), 3.84 (3H, s, CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –76.6 (s, CF3). 
Methyl 2-amino-4,4,4-trifluoro-3-hydroxy-3-methylbutanoate (7m): Following the same 
procedure for the synthesis of compound 7a, from compound 3m (56.2 mg, 0.16 mmol) 
after 72 h was obtained 7m (60.2 mg, 88%). GLC (Supelco β-dex-225, Tcolumn= 60 °C 
(1 min) to 150 °C at 7 °C/min, and to 220 °C at 16 °C/min, trans-7m (major 
diastereomer, 82%): major enantiomer tr = 12.3 min, minor enantiomer tr = 13.2 min; 
cis-7m (minor diastereomer): enantiomer 1, tr = 17.7 min, enantiomer 2, tr = 17.8 min; 
dr trans:cis = 97:3; trans-7m: (major diastereomer): [α]D25  –38.2 (c 0.98, CHCl3, 82% 
ee); 1H NMR (300 MHz, CDCl3) δ 3.79 (4H, s, CH, CH3 overlapped), 1.32 (3H, s, 
CH3); 1H NMR (300 MHz, DMSO-d6, for 7m·HCl) δ 8.82 (3H, br s, NH3), 7.47 (1H, br 
s, OH), 4.10 (1H, s, CH-N), 3.75 (3H, s, CH3), 1.39 (3H, s, CH3);19 13C{1H} NMR (75 
MHz, CDCl3) δ 172.2 (C), 125.8 (C, q, JC-F = 285 MHz), 72.6 (C, q, JC-F = 31 Hz), 55.7 
(br, CH), 52.5 (CH3), 18.1 (CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –80.6 (s, CF3). 
HRMS (ESI) m/z: [M+H]+ calcd for C6H11F3NO3+:  202.0686, found: 202.0684. cis-7m 
(minor diastereomer): representative signals taken from the NMR spectra of the 
diastereomer mixture, 1H NMR (300 MHz, CDCl3) δ 3.83 (3H, s, CH3), 1.44 (3H, s, 
CH3); 19F{1H} NMR (282 MHz, CDCl3) δ –78.6 (s, CF3).  
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